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Introduction: Epidemiological data highlights that South Africa is currently facing a 
quadruple burden of disease of which non-communicable diseases (NCDs) are 
estimated to account for 29% of all deaths. These NCDs include, amongst others, 
cardiovascular disease, type 2 diabetes, hypertension, cancer, chronic lung disease and 
depression. Diabetes has become a major problem worldwide and in South Africa and 
is currently rated as the 5th largest cause of death by Statistics South Africa in 2011. 
This creates an enormous burden of disease on populations and the utilization of herbal 
remedies has escalated in popularity because of this. Buchu water is one of these 
herbal remedies advertised as having anti-diabetic properties. This water is a by-
product of the extraction of the oil from the leaves of Agathosma and is already freely 
available to the public.  
The aim of this study was therefore to use animal models of type 1 diabetes, and 
obesity and insulin resistance to scientifically verify or refute these claims.  
Methods: We utilized male Wistar rats. Two different rat models were used: (i) a type 1 
diabetic model; induced via a once-off intraperitoneal Streptozotocin (40mg/kg) injection 
ablating ~50% of pancreatic beta cells (T1D); (ii) A diet-induced obese model, rendering 
rats insulin resistant after receiving a high caloric diet for 16 weeks. Half of each 
experimental group was treated with diluted Buchu water for a period of 14 weeks and 
16 weeks, respectively, while the rest consumed normal water. Water and food 
consumption were monitored, body weight and intraperitoneal fat measured, blood was 
collected to determine serum glucose and insulin levels, skeletal muscle was removed 
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to test insulin sensitivity using radiolabelled deoxyglucose,  pancreas and skeletal 
muscle harvested and stored in liquid nitrogen for further biochemical analysis.  
Results: One of the main findings of this study was that ingestion of Buchu water 
results in weight loss despite no decrease in food consumption. This occurred in both 
the pathological models and control animals. In the obese animals, this weight loss was 
due to a decrease in intra-peritoneal fat.  
A second important finding was that the ingestion of Buchu water in all instances, 
whether given as treatment (treated with Buchu water 3 weeks after the start of the 
experiment) or as prophylactic (treated with Buchu water from the start of the start  of 
the experiment), resulted in normalization of glucose levels in a type-1 diabetic model 
with residual beta-cell mass.  
An insulin-sensitizing effect was not clearly established in skeletal muscle but this may 
be because of a large variation in values obtained, as well as the use of a slow-twitch 
muscle.  
A definite effect on pancreatic insulin secretion has been demonstrated by raised C-
peptide levels in the diet-induced obese model. 
Conclusion: This study, with regard to the type 1 diabetic model, has confirmed the 
anti-diabetic effect of Buchu water by significantly lowering blood glucose levels of 
fasted and non-fasted blood and normalizing Intraperitoneal glucose tolerance test 
(IPGTT) curves. This was however not so evident in the obese model utilized. Despite 
this, animals lost weight which was mainly intra-peritoneal fat.  
 




Inleiding: Epidemiologiese data dui aan dat daar tans ‘n viervoudige siektelading Suid 
Afrika in die gesig staar. Hiervan is nie-oordraagbare siektes (NCDs) vir ongeveer 29% 
van van sterftes verantwoordelik. Hierdie siektetoestande sluit kardiovaskulêre siektes, 
tipe 2 diabetes, hipertensie, kanker, kroniese longsiektes en depressie in. Diabetes is 
tans ook in Suid Afrika een van die groot gesondheidsprobleme en word deur die MNR 
10de op die ranglys van oorsake van sterftes geplaas. Dit veroorsaak ‘n groot siektelas 
op die populasie in geheel. As gevolg hiervan het die gebruik van natuurlike produkte 
om siektes te behandel, geweldig toegeneem. Buchuwater is een so ‘n natuurlike 
produk wat geadverteer word om anti-diabetiese effekte te hê. Hierdie water is ‘n 
afvalproduk van die ekstraksie van Buchu-olie uit die blare van Agathosma en is alreeds 
vrylik aan die publiek beskikbaar.  
Metodes: Manlike Wistarrotte is vir die studie gebruik. Twee verskillende modelle is 
gebruik naamlik (i) ‘n tipe 1 diabetiese model daargestel deur ‘n enkele intraperitoneale 
Streptozotocin (40mg/kg) inspuiting waarmee ~50% van die betaselle van die pankreas 
vernietig word en (ii) ‘n dieet-geïnduseerde vetsugtige model waar rotte vir 16 weke op 
‘n hoë kalorie dieet geplaas word. Helfte van elke eksperimentele groep diere se 
drinkwater is deur verdunde Buchuwater vervang vir die volle 16 weke. Water- en 
kosinname is gemonitor, liggaamsgewig en intraperitoneale vetgewig bepaal. 
Bloedglukose is gemonitor en intraperitoneale glukosetoleransie kurwes opgestel. Bloed 
is gekollekteer om serum insulienvlakke te bepaal en skeletspier 
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insulienweerstandigheid is bepaal deur die opname van isotoopgemerkte deoksiglukose 
te meet. Pankreata is geoes en in vloeibare stikstof vir biochemiese analise gestoor.  
Resultate: Een van die hoofbevindinge van hierdie studie was dat die inname van 
Buchuwater gewigsverlies in diere teweeggebring het sonder dat hulle kosinname 
verminder het. Dit het in beide modelle, sowel in kontrol diere gebeur. In die vetsugtige 
diere was hierdie verlies as gevolg van verlies van intraperitoneale vet.  
‘N tweede belangrike bevinding was dat die inname van Buchuwater ‘n normalisering 
van bloedglukosevlakke in die tipe 1 diabetiese diere met ‘n betasel reserwe 
teweeggebring het, beide wanneer dit as voorkomend of as behandeling gegee is.  
Sensitisering teenoor die effekte van insulin in die skeletspiere van die vetsugtige model 
rotte kon nie waargeneem word met die inname van Buchuwater nie, deels as gevolg 
van ‘n baie groot variasie in die resultate.  
Effekte van die Buchuwaterinname op die betaselle van die pankreas en 
insuliensekresie is gevind.  
Gevolgtrekking: Met betrekking tot die tipe 1 diabetiese model het die studie die 
antidiabetiese effekte van Buchuwater bevestig deur ‘n beduidende verlaging van 
vastende sowel as nie-vastende bloedglukosevlakke en normalisering van IPGTT 
kurwes teweeg te bring. Hierdie effekte was nie so voor die hand liggend in die 
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Motivation for research 
 
 
South Africa is a country rich in floral biodiversity and cultural diversity [Light et al., 
2005]. The Cape region of South Africa has veldt types with arguably the richest 
composition of indigenous aromatic plant species [Moolla et al., 2007]. Amongst these 
aromatic plants is the genus Agathosma [Moolla et al., 2007]. There are approximately 
150 different species within the genus, which branches from a greater family called 
Rutaceae [Moolla et al., 2007]. These rutacious shrubs are typical of the fynbos 
(vegetation found in the Western Cape province of South Africa) and are particularly 
abundant in the mountainous areas of the Cape [Moolla et al., 2007]. The term “Buchu” 
primarily originated from the Khoisan (indigenous people of the western region of South 
Africa) and was given to any fragrant plant that could be dried and powdered [Moolla et 
al., 2007]. This name includes a wide variety of aromatic plant species, not singling out 
a specific genus [Moolla et al., 2007]. The Khoisan tribes relied on these plant materials 
for many centuries to maintain and/or promote good health. In this era, herbal remedies 
formed the backbone of healthcare and was the central source of medication [Light et 
al., 2005]. Today, the term “Buchu” refers to Agathosma Betulina (round-leaf buchu; 
‘bergboegoe’; short buchu) and Agathosma Crenulata (oval-leaf buchu; ‘anysboegoe’; 
long-leaf buchu) [Moolla and Viljoen, 2008]. 
  
Europeans were first introduced to “Buchu” in the 1650’s, upon their arrival in the Cape 
[Moolla and Viljoen, 2008]. The use of these plants then spread to Europe and America 
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where it was extensively used for medicinal purposes [Moolla and Viljoen, 2008]. 
Recently, more attention has been placed on the organoleptic properties of “Buchu” 
rather than on its impact on health, shifting interest towards oil extraction.  Oils from 
these plants are obtained by means of hydro diffusion, a method called hydrodistillation. 
These oils are typically used in the perfume industry and as flavouring agents to 
enhance fruit flavours [Moolla and Viljoen, 2008]. Currently, Buchu products are virtually 
found in every store, ranging from teabags, water, lotions, tonics, ointments and even 
brandy. These products have been approved by the American Food and Drug 
Administration (FDA), rendering Buchu safe for consumption. 
 
The people of South Africa are faced with many challenges on a daily basis, especially 
where healthcare is concerned. Illnesses such as diabetes and cardiovascular diseases 
is a major source of morbidity and mortality in populations that cannot afford western 
medication [Light et al., 2005]. Such people are left with no other option but to consult 
traditional healers and make use of herbal remedies [Light et al., 2005]. There are many 
concerns associated with the use of indigenous plants in medicine. One of these issues 
stem from the fact that a large portion of knowledge based on herbal usage is 
anecdotal, posing great concern [Light et al., 2005].  The claims that Buchu exerts anti-
microbial, anti- inflammatory, anti-oxidant and diuretic effects have been successfully 
validated by studies reviewed by Moolla and Viljoen [Moolla and Viljoen, 2008]. Claims 
that Buchu has anti-diabetic effects are anecdotal and needs to be validated 
scientifically. To date, only a few studies have been published on the pharmacological 
actions of buchu, underscoring the urgency for research in this regard. 
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Our aim was therefore, on request of the producing company, to determine the anti-
diabetic and insulin sensitizing potential of a watery extract of Agathosma tested in rat 
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1.1. The Digestive System 
 
To maintain an optimal nutritional status, consumption of proteins, fats and 
carbohydrates are required.  
 
Food entering the mouth is physically digested by the continuous grinding and chewing 
action of the teeth [Raven and Johnson, 2001]. In the oral cavity, salivary glands 
secrete mucus which aid in lubrication, provides protection against foreign invaders; 
bacteria, and moisten ingested food [Fabian et al., 2012]. Mucus is a liquid-like 
substance rich in amylase and immune cells [Fabian et al., 2012]. Amylase is an 
enzyme with a catalytic function to hydrolyse carbohydrates, converting starch to 
maltose [Collins et al., 1993].  After mastication, the digestive material in the mouth, 
known as the bolus, makes it way down the oesophagus towards the abdomen [Matsuo 
and Palmer, 2008]. This action is achieved via peristaltic wave-like movements of the 
oesophageal wall [Matsuo and Palmer, 2008]. Glands lining the abdominal wall secrete 
hydrochloric acid (HCI) and proteolytic enzymes, ensuring an acidic environment for 
proper protein denaturation. The material present in the abdomen after absorption is 
called chyme. Chyme makes its way to the intestine through the pyloric sphincter where 
it is further digested. The small intestine, specifically the duodenum, is the main site of 
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absorption. In the small intestine an enzyme called cholecystokinin (CCK) is secreted, 
preventing gastric emptying into the intestine and stimulating the release of digestive 
juices [Powers and Pappas, 1989]. This enzyme stimulates organs such as the liver and 
pancreas to assist with digestion by secreting bile and pancreatic juice, respectively.  
Bile travels from the liver to the duodenum via a common hepatic duct, where it 
emulsifies and degrades fat molecules. Pancreatic juice contains bicarbonate, in 
addition to other digestive enzymes which neutralizes the acidic chyme [Fieker et al., 
2011]. Amylase secreted by the pancreas and intestine hydrolyzes the last traces of 
starch in chyme. Maltose gets broken down into glucose with the aid of the enzyme 
maltase. These glucose molecules are transported by the blood to the rest of the body, 
where they are used as energy. In the large intestine, no digestion takes place but water 
and ions are absorbed. Waste material exits the gastrointestinal tract via the rectum and 
is expelled by the anus. Figure 1 illustrates the digestion of starch only, as our main 















































Figure 1: Breakdown of complex polysaccharides  
 
 
Starch entering various compartments of the digestive system is broken down by 
specific enzymes, forming maltose. In the small intestine, maltase catalyzes the 
production of glucose from maltose. These glucose molecules are released into 
circulation and transported to a whole range of tissue to sustain life.  
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1.2. Glucose transport across the intestinal epithelium 
 
Glucose is an important nutrient, playing a vital role in many biological processes within 
mammalian cells [Shah et al., 2012]. These processes include cellular homeostasis and 
metabolism. In order for glucose to execute its function it has to make its way across the 
lipid bilayer of the cell. This mode of transportation is achieved with the help of carrier 
proteins, namely, glucose transporters (GLUTs) and sodium-glucose cotransporters 
(SGLT) [Bucci et al., 2011]  
 
After a meal, dietary glucose and sodium (Na+) concentrations increase within the 
intestinal lumen. Epithelial cells lining the walls of the small intestine maintain 
homeostasis by transporting molecules and/or ions out of the cell. A low cytoplasmic 
Na+ concentration is established in the enterocyte via active transport. The sodium-
potassium (Na+/K+) ATPase pump, located on the basolateral membrane, lowers the 
cytoplasmic sodium concentration by actively transporting three sodium ions out of the 
enterocyte [Srichamroen, 2007]. This results in an ionic imbalance. To restore balance, 
two potassium ions found in blood vessels have to move against its concentration 
gradient into the cell with the help of adenosine triphosphate (ATP). The sodium-
glucose co-transporter 1 (SGLT-1) allows Na+ in the lumen to be transported into the 
enterocyte. Energy produced by sodium ions moving down their concentration gradient 
makes it possible for glucose to move against its concentration gradient [Steel and 
Hediger, 1998; Srichamroen, 2007]. This results in high levels of glucose accumulation 
within the cytosol. These glucose molecules move into circulation via facilitated diffusion 
to the necessary cells [Steel and Hediger, 1998, Srichamroen, 2007]. Below is a 
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diagrammatic figure depicting the movement of glucose from the intestine to its specific 















Figure 2: Glucose transport across the enterocyte [Wright, 1998]. 
 
       sodium-glucose co-transporter             sodium-potassium (Na+/K+) ATPase pump 
 
       glucose transporter 2 
 
 
The diagram is a reconstruction of Wright, 1998. The sodium-glucose co-
transporter and the Na+/K+ ATPase pump allow sodium ions to be transported 
from the lumen across the enterocyte into circulation. The movement of sodium 
ions provide enough energy enabling the transport of glucose into the enterocyte 
which enter circulation via facilitated diffusion.  
 
 
1.3. The Pancreas 
 
The pancreas is a gland situated in the abdominal cavity, partially connected to the 
duodenum [Torpy et al., 2012]. This gland functions both as an exocrine organ, 
secreting digestive juice into the small intestine, and an endocrine organ, producing 
hormones which regulate metabolism [Novak, 2008]. 
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1.3.1. Exocrine pancreas 
 
The exocrine portion of the pancreas is a major contributor to pancreatic mass. In these 
regions acinar cells are present [Jiang et al., 2008]. Acinar cells form glands which 
secrete various enzymes necessary for digestion [Jiang et al., 2008, Logsdon and Ji, 
2013]. The journey of these enzymes to the duodenum is facilitated by pancreatic ducts 
[Logsdon and Ji, 2013]. Cells lining the duct secrete a watery, bicarbonate-rich fluid 
which flushes digestive enzymes into the small intestine [Afroze et al., 2013]. Intestinal 
enzymes break down proteins, carbohydrates and fats into their respective monomers; 
allowing effortless absorption. 
 










1.3.2. Endocrine pancreas 
 
Interacinar cells are irregularly shaped regions within the pancreas, known as the islets 
of Langerhans [Steiner et al., 2010]. The presence of these islets were first documented 
in 1869 by a German physician, Paul Langerhans [Islam, 2009]. A healthy adult 
pancreas contains 1 million islets which accommodate approximately 2% of the 
pancreas [Leoni and Roman, 2010]. The islets of Langerhans are composed of many 
cells, playing a pivotal role in regulating glucose metabolism.   
Digestive Enzyme Function 
Amylase Digest starch 
Chymotrypsin, Trypsin and Carboxypeptidase Digest protein 
Lipase Digest Triglycerides 
Cholesterol esterase Digest cholesterol 
Ribonuclease and deoxyribonuclease Digest nucleic acid 
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The α- and β- cells regulate blood glucose levels by secreting glucagon and insulin 
respectively [Soria et al., 2010]. These hormones have opposite effects, thus ensuring 
that fasting blood glucose levels remain within a normal range (4 to 8 mmol/L) [Andrews 
et al., 1998]. Glucagon, secreted by α-cells, increases the concentration of plasma 
glucose by stimulating glycogenolysis and gluconeogenesis by the liver. β-cells operate 
inversely, secreting insulin which stimulates glucose uptake by peripheral cells and 
enhances glycogenesis. Pancreatic β-cells will be discussed in more detail below.  
 
1.4. Pancreatic response to hyperglycemia 
Pancreatic β-cells respond to hyperglycemia by increasing glucose metabolism and 
ATP production [Layden et al., 2010]. This, in turn, increases the cytoplasmic ATP/ADP 
ratio, resulting in the closure of potassium channels [Layden et al., 2010]. These cells 
undergo depolarization causing voltage-gated calcium channels to open, allowing 
movement of extracellular calcium into the cell [Layden et al., 2010]. Calcium acts as an 
intracellular signal, stimulating exocytosis of insulin-containing vesicles and insulin 
Endocrine cell Hormone Total islet cells 
(%) 
Beta cell (β) Insulin and Amylin 65-80 
Alpha cell (α) Glucagon 15-20 
Delta cell (δ) Somatostatin 3-10 
Gamma cell (γ) Pancreatic polypeptide 3-5 
Epsilon cell (ε) Ghrelin <1 
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secretion into circulation [Li et al., 2007]. The secreted insulin is stored in mature 
























Figure 3: Insulin release by pancreatic β-cells [Layden et al., 2010] 
 
The diagram is a reconstruction of Layden, 2010. Step 1, when β-cells are 
exposed to hyperglycemia they adapt by increasing metabolism. Step 2, an 
increase in metabolism causes ATP levels to rise, triggering the closure of 
potassium channels. Step 3, β-cells depolarize and initiate the opening of calcium 
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1.5. The link between insulin action and diabetes mellitus 
 
1.5.1. Insulin biosynthesis 
When β-cells are exposed to hyperglycemia, certain pathways such as the IRS-2/PI-3 
kinase/p70 s6k and CaM kinase pathway are activated. These kinases phosphorylate 
transcription factors involved in insulin transcription. Transcription factors interact with 
the promoter region of the insulin gene, transcribing mRNA. Insulin mRNA is translated 
to preproinsulin in the rough endoplasmic reticulum (ER) [Hartley et al., 2009]. A 
signalling peptide, attached to preproinsulin, directs movement into the lumen of the 
rough ER. Enzymes inside the lumen cleave the signalling peptide, converting 
preproinsulin to proinsulin. Three disulfide bonds hold proinsulin intact after folding 
[Yang et al, 2010]. Shuttle vesicles transport proinsulin from the ER to the golgi 
apparatus [Hartley et al., 2009]. In the golgi, proinsulin is packaged into immature 
secretory vesicles containing endoprotease and carboxypeptidase E [Robinson, 2013]. 
These enzymes cleave proinsulin, producing insulin and c peptides which are released 
during exocytosis [Halban and Irminger, 2003]. Insulin entering circulation binds to its 
target cell, activating an entire host of signalling cascades which stimulate glucose 
uptake, lipogenesis, protein synthesis and glycogenesis. All these processes will be 









































Figure 4: Insulin synthesis and secretion [Ren et al., 2007] 
 
The diagram is a reconstruction of Ren, 2007. Hyperglycemia stimulates the 
transcription of insulin mRNA which is translated to preproinsulin on the 
endoplasmic reticulum. Preproinsulin undergoes various cleavage reactions 
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1.5.2. Insulin action in regulating glucose homeostasis 
Insulin is the most potent anabolic hormone, secreted primarily in response to 
hyperglycemia [Satiel and Pessin, 2002]. This hormone signals a cascade of events 
which promote glucose uptake, glycogenesis, lipogenesis, and protein synthesis; while 
inhibiting pathways and proteins involved in glucose production. Binding of insulin to the 
insulin receptor initiates a conformational change that elicits autophoshorylation and 
activates enzyme activity. The insulin receptor is a tetrameric protein which consists of 
two α subunits that protrude from the cell membrane and two transmembrane β 
subunits connected by disulphide bonds [Dominici et al., 2005]. Each β-subunit 
comprises a carboxyl terminus with three tyrosine residues located in the cytoplasmic 
region. Once phosphorylated, tyrosine motifs recruit src homology 2 (SH2) or 
phosphotyrosine binding (PTB) domain containing adapter proteins [Cipok et al., 2006; 
Kim and Sang, 2007]. 
Insulin receptor substrate (IRS), a PTB protein, binds to the insulin receptor and 
provides docking sites for downstream SH2 proteins. IRS plays a central role in all cells, 
linking receptor tyrosine kinases to, amongst others, the PI-3K/PKB pathway [Guo et al., 
2006]. Tyrosine phosphorylated IRS recruits, binds and activates the regulatory subunit 
(p85) of the heterodimeric phosphatidylinositol 3-kinase (PI-3K) protein, relieving the 
inhibitory effect of the p110 catalytic subunit [Fröjdö et al., 2009; Das et al, 2013]. PI-3K 
can also bind directly to a phosphorylated tyrosine kinase receptor. P1-3K activation 
results in the migration of the protein to the cell membrane. At the cell membrane PI-3K 
interacts with phosphatidylinositol (PtdIns) 4, 5-bisphosphate (PIP2), catalyzing the 
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phosphorylation of PIP2 to PtdIns 3, 4, 5-trisphosphate (PIP3) [Satiel and Pessin, 2002]. 
PIP3 has a high affinity for intracellular proteins containing a pleckstrin homology (PH) 
domain [Das et al, 2013]. These phospholipids recruit phosphoinositide dependent 
protein kinase 1 (PDK1), PDK2 and serine/threonine protein kinase B (PKB) to the 
intracellular membrane where they interact and activate one another [Fröjdö et al., 
2009]. PIP3 is able to prime PKB for phosphorylation by initiating a conformational 
change which allows easy accessibility to threonine 308 (Thr 308) residues. At the 
cytoplasmic membrane PDK2 phosphorylates PKB on its serine 473 (Ser 473) site 
subsequently increasing its affinity for PDK1, phosphorylating the Thr 308 residue of 
PKB. Full activation of PKB requires dual phosphorylation on both Thr 308 and Ser 473 
sites. Once the PI3K/PKB pathway is activated, varied downstream kinases and genes 




















Figure 5: PKB/Akt activation pathway [Turban and Hajduch, 2011]  
The diagram is a reconstruction of Turban and Haiduch, 2011. Binding of insulin 
to the insulin receptor triggers autophosphorylation, resulting in the 
phosphorylation and activation of an insulin receptor substrate protein, and 
phosphatidylinositol 3-kinase (PI-3K). The conversion of phosphatidylinositol 
(PtdIns) 4, 5-bisphosphate (PIP2) to PtdIns 3, 4, 5-trisphosphate (PIP3) is 
catalyzed by PI-3K. PIP3 recruits protein kinase B (PKB) to the plasma membrane 
where it is activated by phosphoinositide dependent protein kinase 1 (PDK1) and 
phosphoinositide dependent protein kinase 2 (PDK2).     
 
 
1.5.3. Insulin signalling pathway in skeletal muscle 
In skeletal muscle, activated PKB/Akt phosphorylates various proteins capable of 
lowering blood glucose levels by increasing glucose uptake, glucose oxidation and 
glucose storage. These cells combat hyperglycemia via the activation of numerous 
processes which will be discussed below.   
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1.5.3.1. Glycolysis and Glycogenesis 
Active PKB/Akt promotes the translocation of glucose transporter 4 (GLUT 4) to the 
plasma membrane, stimulating glucose uptake. The mechanical procedure of GLUT 4 
translocation will be discussed in the section “GLUT 4 translocation to the plasma 
membrane”. Glucose is a monosaccharide with many fates which are essential for 
sustaining life, e.g. it can either undergo glycolysis, for adenosine triphosphate (ATP) 
production, or be stored as a reserve fuel. The term glycolysis is derived from two 
Greek words, ‘Glykys’ meaning sweet and ‘lysis’ referring to the ability to split or break. 
Glycolysis is a series of metabolic processes which provides a quick burst of energy by 
degrading one molecule of glucose [Pelicano et al., 2006]. An in depth review on the 
glycolytic pathway, will be given in the section “Skeletal muscle metabolism”. Excess 
glucose in skeletal muscle is stored as glycogen. PKB/Akt phosphorylates glycogen 
synthase kinase 3 (GSK-3), alleviating its inhibitory effect on glycogen synthase (GS) 
thus promoting glycogen synthesis.  
1.5.3.2 GLUT 4 translocation to the plasma membrane 
In the presence of insulin, glucose enters the cell by facilitated diffusion, a passive 
process which requires no energy [McCarthy and Elmendorf, 2007]. The proteins 
responsible for glucose movement into the skeletal muscle and adipose tissue are 
glucose transporters, GLUT 1 and GLUT 4 [McCarthy and Elmendorf, 2007]. GLUT 1 is 
responsible for basal glucose uptake, and GLUT 4 for insulin-stimulated glucose uptake. 
These 12 membrane spanning transporters play a crucial role in maintaining blood 
glucose homeostasis [McCarthy and Elmendorf, 2007]. In the absence of insulin 
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stimulation, GLUT 4 continuously circulates between the plasma membrane and 
intracellular storage vesicles [McCarthy and Elmendorf, 2007]. More than 90% of GLUT 
4 is localized within endosomal recycling compartments, while only a few are found at 
the cell surface [Thong et al., 2005]. Insulin shifts the movement of GLUT 4 containing 
vesicles towards the plasma membrane by increasing the rate of exocytosis [Thong et 
al., 2005]. The translocation of GLUT 4 is governed by two pathways, PI-3K dependent 
pathway and PI-3K independent pathway, which will be discussed in more detail. 
1.5.3.2.1. PI-3K dependent pathway 
Signalling events that set this pathway into motion are initiated by the binding of insulin 
to its receptor triggering a cascade of phosphorylation events [Chang et al., 2002; 
McCarthy and Elmendorf, 2007]. Tyrosine phosphorylated IRS catalyzes the activation 
of PI-3K, which in turn, leads to PIP3 generation [McCarthy and Elmendorf, 2007]. 
These phospholipids recruit pleckstrin homology (PH) domain containing proteins to the 
membrane where they are activated [Smith et al., 2011]. Both PKB/Akt and atypical 
protein kinase c (aPKC) are phosphorylated by PDK1 on Thr 308 and Thr 410 residues, 
respectively [Thong et al., 2005]. The precise mechanistic action of aPKC is not clear, 
however, it appears to have effects on both intracellular and surface target events of 
GLUT 4 trafficking [Thong et al., 2005]. There are many other proteins involved in GLUT 
4 trafficking, docking and fusion such as Rab GTPase activity proteins, e.g. As160. 
Basally, As160 associates with the GLUT 4 vesicles, hydrolyzing Rab GTP to RabGDP 
[McCarthy and Elmendorf, 2007]. This inactive form of Rab prevents GLUT 4 
translocation to the plasma membrane [McCarthy and Elmendorf, 2007]. Upon insulin 
Stellenbosch University  https://scholar.sun.ac.za
16 
 
stimulation, PKB/Akt phosphorylates As160 on specific serine (Ser 588) and tyrosine 
(Tyr 642) residues, causing it to dissociate from the vesicle [Smith et al., 2011]. 
Phosphorylated As160 recruits and binds to an accessory protein, 14-3-3, which inhibits 
GAP activity towards Rab [McCarthy and Elmendorf, 2007]. The equilibrium shifts 
towards a more active GTP loaded Rab, promoting GLUT 4 trafficking [Smith et al., 
2011]. Several studies have shown that PI-3K activation is necessary but not sufficient 
for insulin stimulated GLUT 4 translocation, thus shifting attention toward PI-3K 
independent pathways [Chiang et al., 2001]. 
1.5.3.2.2. PI-3K Independent pathway (CAP-Cbl-TC10 pathway) 
 
Activation of one PI-3K independent pathway depends on tyrosine phosphorylation of a 
proto-oncogene. Upon insulin stimulation, insulin receptors are autophosphorylated 
recruiting adaptor proteins, APS (adapter containing pleckstrin homology domain and 
Src homology (SH) 2 domain) and CAP (Cbl associated protein), to the plasma 
membrane [Chang et al., 2002]. CAP phosphorylates tyrosine residues on CbI by 
interacting with proline-rich domains [Chang et al., 2002]. This triggers the migration of 
the dimeric CAP-Cbl complex towards caveolin enriched lipid rafts [Liu et al., 2002]. The 
process of migration is facilitated through the association of an amino-terminal SH2 
domain on CAP with the lipid raft protein, flotillin [Chang et al., 2002; Chiang et al., 
2001]. Tyrosine phosphorylated Cbl recruits an adaptor protein, CrkII, along with C3G 
towards the lipid raft domain on the plasma membrane [McCarthy and Elmendorf, 
2007]. This occurs in two stages; firstly Cbl binds to the SH2 domain of CrkII and 
secondly the SH3 domain of CrkII interacts with the proline domain of C3G, forming the 
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CrkII-C3G complex [Liu et al., 2002; Chiang et al., 2001]. Once translocated, the CrkII-
C3G complex brings C3G into close proximity with the Rho family protein, TC10, 
residing in the raft domains of the membrane [Chang et al., 2002; Chiang et al., 2001].  
This interaction catalyzes the hydrolysis of GTP to GDP, rendering TC10 active [Chiang 
et al., 2001]. The activation of TC10 plays a critical role in the regulation of GLUT 4 
translocation, docking and fusion with the plasma membrane [Chiang et al., 2001]. 
Varies studies have showed that TC10 interferes with actin dynamics and cytoskeletal 
arrangement, facilitating exocytosis of GLUT 4 [Thong et al., 2005; Chiang et al., 2001]. 
 
1.5.3.2.3 PI-3K Independent pathway (AMPK pathway) 
 
For many years living organisms persevered by mechanistically adapting to nutritional 
and environmental stressors. In this section of the review, compensatory adjustments in 
response to contraction/exercise, will be discussed. When skeletal muscles are 
exposed to exercise, an intramuscular energy change occurs initiating numerous 
metabolic responses to restore energy balance [Winder, 2001]. One of the ways in 
which these cells counteract high-energy phosphate depletion as a result of exercise, is 
by alerting the AMP-activated protein kinase (AMPK) low fuel warning system [Winder, 
2001; Nielsen et al., 2003] . This system operates by switching off ATP utilizing 
processes, such as biosynthetic pathways while switching on ATP-generating pathways 
that include fatty acid oxidation and glucose uptake [Hardie, 2004; Russell et al., 1999; 
Luiken et al., 2003; Kudo et al., 1995; Fryer et al., 2000]. AMPK is a heterotrimer that is 
ubiquitously expressed in cells [Nielsen et al., 2003]. These proteins consist of a 
catalytic alpha subunit containing the kinase domain and two regulatory subunits termed 
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beta and gamma [Sakamoto et al., 2005]. All these subunits are necessary for the 
complete activation of AMPK [Winder, 2001]. The degree of activation depends on 
muscle glycogen concentration, pre-exercise diet, exercise duration, exercise intensity 
and training status [Nielsen et al., 2003; Winder, 2001; Wojtaszewski et al, 2003]. During 
muscle contraction, AMPK becomes allosterically activated by an increase in the 
AMP:ATP and creatine:phosphocreatine ratio [Wojtaszewski et al, 2003; Hayashi et al., 
1998; Ponticos et al., 1998; Hardie and Carling,1997]. Once activated, AMPK stimulates 
GLUT 4 translocation to the plasma membrane by phosphorylating As160, similar to the 
pathway activated by PKB/Akt, thereby increasing glucose transport [Nielsen et al., 
2003]. An increase in the level of glucose molecules within the cell and the activation of 
catabolic processes result in ATP regeneration [Sakamoto et al., 2005; Hayashi et al., 
1998; Fryer et al., 2000; Hardie and Carling,1997]. Figure 6 summaries the regulation 
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Figure 6: Regulation and activation of AMPK [Winder, 2001] 
(      ): Inhibit     +: Stimulate       : Decrease 
(a) Myokinase and creatine phosphokinase (CPK) are two enzymes that maintain 
physiologically normal ATP levels in skeletal muscle in response to contraction. 
During exercise, Myokinase increases the AMP concentration within the muscle 
by transferring a phosphate from one ADP to another ADP molecule. CPK 
stimulates the transfer of a phosphate from CP to ADP, forming ATP. (b)[a 
graphical modification of Winder, 2001] As a result, high levels of AMP can either 
stimulate AMPK activity directly or indirectly via AMPKK. A decrease in the 
concentration of creatine phosphate removes/relieves its inhibitory effects on 
AMPK activation.   
 
 
1.5.4. Regulators of the insulin pathway   
 
The P1-3K pathway plays a critical role in regulating a wide variety of biological 
processes through the generation of a potent second messenger, PIP3 [Sly et al., 
2003]. These processes include cell proliferation, growth, differentiation and survival 
[Kalesnikoff et al., 2002]. PIP3 recruits and activates many PH domain containing 
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     AMPK 
    Creatine phosphate 
    AMPKK 
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proteins, initiating a cascade of events necessary for cell survival [Cond́e et al., 2011]. 
Cellular PIP3 levels need to be tightly regulated to prevent abnormal cell proliferation 
and impaired glucose metabolism [Cond́e et al., 2011; Kennah et al., 2009]. These 
levels are kept under control by lipid phosphatases, namely phosphate and tensin 
homolog deleted on chromosome 10 (PTEN) and Src homology 2 containing inositol-5-
phosphatase (SHIP) [Chow and Baker, 2006]. Both of these phosphatases modulate 
the PI-3K pathway by dephosphorylating PIP3, thus downregulating PKB/Akt activation. 
1.5.4.1. PTEN 
 
PTEN was first identified in 1997; and has a large region of homology to chicken tensin, 
bovine auxilin, and a protein tyrosine phosphatase domain [Waite and Eng, 2002]. This 
54 KDa lipid phosphatase consists of three structural domains: a C2, amino-terminal 
and a tail domain [Parsons, 2004]. The amino-terminal domain contains a phosphatase 
catalytic region composed of β sheets surrounded by alpha helices [Waite and Eng, 
2002]. This catalytic region has an enlarged active site that allows phosphoinositide 
substrates to enter the site with ease [Simpson and Parsons, 2001]. The width and 
depth of the active site is consistent with PTENs ability to dephosphorylate lipid 
substrates [He et al, 2010]. The C2 domain is required for efficient binding of PTEN to 
the membrane [Parsons, 2004; Waite and Eng, 2002].  Studies have shown PTEN to 
have a higher affinity for membrane bound phospholipids, ‘in vitro’. The tail domain 
contains a PDZ (Threonine, Lysine, Valine) -binding motif and a PEST (Proline, 
Glutamic acid, Serine, and Threonine) motif responsible for protein-protein interactions 
and PTEN stability, respectively [Waite and Eng, 2002]. PTEN appears to be 
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ubiquitously expressed within cells and its activity depends on PIP3 levels and/or post-
translational modification [Gericke et al., 2006; Chow and Baker, 2006]. The 
phosphatase activity of PTEN is down regulated by modifying it in two ways, either via 
phosphorylation of the tail domain or oxidation of the catalytic domain [Wang and Jiang, 
2008]. Casein kinase 2 (CK2) is considered to be responsible for a large portion of 
PTEN phosphorylation [Gericke et al., 2006]. Torres and Pulido (2001) demonstrated 
that CK2 phosphorylates PTEN on serine (Ser370, Ser380 and Ser 385) and threonine 
(Thr383) residues, ‘in vivo’ [Waite and Eng, 2002]. Phosphorylation of the tail domain 
causes a conformational change which masks the PDZ domain and enhances PTEN 
stability [Waite and Eng, 2002; Gericke et al., 2006]. It is widely accepted that 
phosphorylation of PTEN is required for its inactivation to maintain PTEN cytosolic 
levels, prevent proteasomal degradation and slow PTENs interaction with phospholipids 
[Wang and Jiang, 2008; Waite and Eng, 2002]. GSK-3 has been reported to 
phosphorylate the tail domain of PTEN on Ser 362 and Thr 366 residues [Wang and 
Jiang, 2008]. 
 
PTEN can be inactivated through oxidation which is induced by reactive oxygen species 
(ROS). Insulin triggers a complex signalling cascade which enhances the production of 
ROS [Espinosa et al., 2009]. Insulin stimulated ROS, catalyzed by NADPH oxidase, 
oxidizes cysteine (Cys 71 and Cys 124) residues in the catalytic domain of PTEN [Wang 
and Jiang, 2008; Espinosa et al., 2009]. This oxidative process inhibits PTEN and 
allows PIP3 levels to rise, rendering PKB/Akt active. PTEN knockout mice are 
embryonically lethal whereas heterozygotes develop a variety of cancers [Sly et al., 
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2003]. Overexpression of PTEN induces cell cycle arrest and results in a metabolic 
switch from aerobic glycolysis to anaerobic pathways. This protects cells from 
oncogenic transformation, thus promoting a healthier metabolism [Simpson and 
























Figure 7: PTEN structure [Wang and Jiang, 2008] 
 
Phosphate and tensin homolog deleted on chromosome 10 (PTEN) consists of 
three major structural domains: an amino-terminal (phosphatase domain), a C2 
domain and a tail domain. PTEN is regulated by glycogen synthase kinase 3 
(GSK3) and casein kinase 2 (CK2) via the phosphorylation of specific serine and 
threonine residues. Other factors such as reactive oxygen species can also 












The SHIP family of phosphatases includes two members, SHIP-1 and SHIP-2, which 
are isoforms of each other [Braccini et al., 2012]. The expression of SHIP-1 
phosphatase is restricted to hematopoietic cells while SHIP-2 is ubiquitously expressed 
in the brain and skeletal muscle [Braccini et al., 2012; Kennah et al., 2009; Cond́e et al., 
2011]. The SHIP-2 isoform contains an amino terminal, a central catalytic domain and a 
C-terminus [Condé et al., 2011]. The amino-terminal SH2 domain and the catalytic 
domain is essential for binding proteins which consist of phosphorylated tyrosine 
residues and molecules exerting phosphatase activity on PIP3, respectively. The C-
terminus is made up of a proline rich region and a SAM (sterile alpha motif) domain, 
which are important for SHIPs translocation to the plasma membrane [Sly et al., 2003]. 
SHIP-2 is an important regulator of the PI-3K pathway especially in β-cells. 
A study done by Laura and colleagues showed a complete lack of SHIP-2 in mice to be 
linked to prenatal death and hypoglycaemia [Sly et al., 2003]. Various studies on SHIP-
2 heterozygous mice have demonstrated enhanced insulin sensitivity, upon insulin 
stimulation [Cond́e et al., 2011]. These mice exhibited higher levels of GLUT 4 
translocation and glycogen synthesis when compared to normal control mice [Cond́e et 
al., 2011].  
 A balance between the activation and inhibition of lipid phosphatases plays a critical 
role in glucose homeostasis and cancer development [Cond́e et al., 2011]. It has been 
reported that phosphatases have a negative impact on insulin resistance associated 
with obesity [Gupta and Dey, 2009]. Insulin resistance appears to be linked to an 
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increase in phosphatase expression and/or activity in skeletal muscle and adipose 
tissue [Sly et al., 2003]. Phosphatases are involved in many biological processes, thus 











Figure 8: The difference between the SHIP structure [Lazar and Saltiel, 2006] 
The Src homology 2 containing inositol-5-phosphatase 1 (SHIP 1) and Src 
homology 2 containing inositol-5-phosphatase 2 (SHIP 2) is the presence of a 
SAM domain. SHIP 2 consists of an amino-terminal SH2 domain, a central 
catalytic domain and a C-terminus. The C-terminus is made up of a proline rich 
region and a SAM domain, which are important for SHIPs translocation to the 
plasma membrane 
 
1.5.5. Role of insulin in the development of diabetes 
The presence of plasma insulin in response to a meal or high blood glucose levels is 
crucial in maintaining glucose homeostasis. A defect in insulin secretion or insulin action 
would have adverse effects on metabolism as well as on an individual’s quality of life. 
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Diabetes mellitus is a disease which manifests as a result of an impairment in insulin 
response by peripheral tissue or an impairment of pancreatic insulin secretion.  
1.6. Diabetes Mellitus  
The World Health Organization estimated that 347 million people worldwide have 
diabetes mellitus, with approximately 80% of diabetic deaths occurring in low and 
middle income countries [Mathers and Loncar, 2006; WHO, 2014]. The earliest 
descriptive report of diabetes dates back to 1550 BC [Moitra and Meiler, 2006]. In this 
era, a physician, Mesy Ra, documented frequent urination (polyuria) on Egyptian 
papyrus, a characteristic symptom of the diabetic condition [Moitra and Meiler, 2006]. 
According to World Health Organisation (WHO), diabetes will be the 7th leading cause of 
death by the year 2030. Diabetes mellitus is a chronic disease associated with many 
complications and occur in individuals’ of all ages. Diabetes is characterized by 
hyperglycemia which originates as a result of pancreatic β-cells not being able to 
produce sufficient insulin or the inability of target tissues to respond to insulin action. 
There are three main types of diabetes: Type 1, Type 2 and gestational diabetes. 
Diabetic individuals require lifelong management as there is as yet no cure for diabetes, 
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1.6.1 Type 1 Diabetes 
Type 1 Diabetes (T1D) is an organ specific autoimmune disease caused by the 
immunological destruction of insulin producing pancreatic β-cells [Atkinson and 
Elsenbarth, 2001; Narendran et al., 2003; Atkinson and Elsenbarth, 2001]. T1D was 
formerly known as juvenile onset or insulin dependent diabetes mellitus, a term which is 
no longer used [Atkinson and Elsenbarth, 2001]. The American Diabetes Association 
(ADA) eliminated these terms based on the fact that not all T1D individuals are children 
or insulin dependent at onset [Atkinson and Elsenbarth, 2001]. T1D is a disorder of all 
ages with peak expression in children between the ages of 10-14 years [Atkinson and 
Elsenbarth, 2001].  It should be emphasized that patients with T1D are at an increased 
risk for developing other autoimmune diseases such as Graves’ disease, Addison’s 
disease and hypothyroidism [Atkinson and Elsenbarth, 2001]. An interplay between 
genetic susceptibility and environmental factors trigger the initial stages of pre-diabetes, 
followed by insulitus [Barker, 2008]. The progression of pre-diabetes to overt diabetes is 
characterised by a loss of the first phase insulin response to intravenous glucose, 
glucose intolerance and loss of serum C-peptides [Thrower and Bingley, 2010]. Upon 
the development of overt diabetes the total mass of working β-cells is approximately 10-
20%, corresponding with the reduced ability of the pancreas to produce sufficient insulin 
to maintain normoglycemia [Barker, 2008]. Once this point has been reached, insulin 
administration should be adhered to for life to reinforce a patient’s survival [Thrower and 
Bingley, 2010]. Insulin treatment serves to be very beneficial by lowering blood glucose 
levels and stimulating residual β-cells, to regain functionality [Barker, 2008]. 











Figure 9: The pathogenesis progression of type 1 diabetes [Atkinson and 
Elsenbarth, 2001]. 
β-cell dysfunction is triggered by genetic and environmental factors, 
subsequently followed by insulitis. Infiltration of inflammatory cells or proteins 
impairs β-cell function, ultimately leading to inflammation and β-cell death.  The 
release of β-cell debri as a consequence of apoptotic death further exacerbates 
the autoimmune response, promoting overt diabetes. IAA, insulin autoantibodies; 
ICA, islet cell autoantibodies; GADA, autoantibodies to glutamic acid 
decarboxylase.  
 
1.6.1.1 Pancreatic β-cell dysfunction 
Inflammatory infiltration of β lymphocytes, macrophages, CD8 and CD4 T cells, initiates 
the destruction of β-cells via the activation of specific apoptotic pathways [Atkinson and 
Elsenbarth, 2001]. Potential mechanisms of β-cell destruction include pro-inflammatory 
cytokines, Fas/Fas ligand and reactive oxygen species [Atkinson and Elsenbarth, 2001]. 
These inflammatory destructive factors interact with β-cell cytokine receptors (tumor 
necrosis factor receptor (TNFR), interferon-gamma receptor (IFN-γR) and Interleukin-1β 
receptor (IL-1βR)), activating the MAP kinase pathway and a diverse group of 
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transcription factors, STAT-1 (signal transducer and activator of transcription-1) and NF-
κβ. This ultimately results in functional impairment and apoptotic β-cell death [Atkinson 
and Elsenbarth, 2001]. Damaged β-cells release cell debris and auto-antigens which 
are recognized by auto-reactive effector T-cells, exacerbating the autoimmune 
response, thus promoting T1D [Thrower and Bingley, 2010]. 
The autoimmune destruction of β-cells varies widely between individuals and can occur 
over months and even years [Thrower and Bingley, 2010]. The rate at which destruction 
proceeds depends on an individual’s tolerance to regulate the immune response 
[Ziegler and Nepom, 2010]. Therefore, prolonging complete eradication of β-cells would 
serve to be favourable in a clinical setup. 
1.6.1.2 β-cell mass 
As previously stated, β-cells secrete insulin which regulates glucose homeostasis by 
targeting various tissues. For this reason, β-cell mass is vital in the manifestation of 
diabetes mellitus and should be closely monitored. β-cell mass are dynamic 
components which readily adapt to changes in insulin demand or glucose 
concentrations. To maintain an optimal glucose level, an exquisite balance exists 
between insulin biosynthesis, stimulation and secretion.  
The quantitative amount of β-cells present can be calculated based on the interplay 
between β-cell growth and loss. There are three mechanisms involved in β-cell 
expansion which include replication of existing differentiated β-cells, neogenesis of β-
cells from undifferentiated precursors and hypertrophy [Masiello, 2006]. A reduction in 
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β-cell mass is associated with hypotrophy and β-cell death as a result of apoptosis, 
and/or necrosis.  Altering any of these mechanisms would result in a change in β-cell 
mass.  
Under normal conditions, β-cell growth and remodeling occurs prenatally, and continues 
for a short period of time after birth [Masiello, 2006]. During this time, β-cell replication is 
enhanced followed by a surge in β-cell neogenesis. This results in β-cell growth as a 
consequence of apoptotic activity being kept at a low level. The rate at which β-cell 
replication, neogenesis and apoptosis occur soon stabilizes as individuals enter 
childhood and adulthood, thus maintaining a relative constant β-cell mass [Masiello, 
2006]. Various factors contribute to a reduction in β-cell mass, such as old age and the 
exposure of β-cells to cytotoxic factors, stimulating apoptosis.   
1.6.1.3 β-cell neogenesis 
As a result of β-cell dysfunction or death, research has shifted its focus to β-cell 
neogenesis. β-cell neogenesis is a mechanism that triggers the generation of new β-
cells from precursor cells [Paris, 2004]. These precursor cells originate from (i) ductal 
cells (budding from duct epithelium), (ii) differentiated pancreatic cells through a process 
called transdifferentiation and (iii) intra islet precursors [Paris, 2004]. β-cell neogenesis 
is a well documented process that is involved in β-cell mass expansion and 
maintenance, when exposed to increased insulin demand. For this reason, β-cell 
neogenesis would serve to be beneficial in treating diabetes mellitus. There are various 
transcription factors promoting β-cell neogenesis which will be discussed in more depth. 
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1.6.1.4 Transcription factors promoting β-cell neogenesis 
Transcription factors control several biological processes such as β-cell differentiation, 
proliferation, apoptosis, and pancreatic development [Rocques et al, 2007]. The 
regulation of transcription factors is of utmost importance due to the link between β-cell 
dysfunction and diabetes. In this study we will be focusing on pancreatic duodenal 




The pancreatic duodenal homeobox 1 protein is a homeodomain containing 
transcription factor that is essential for early pancreatic development and β-cell survival 
[Yang et al., 2012]. During early prenatal development, Pdx-1 is mainly expressed in 
pancreatic progenitor cells, later giving rise to endocrine and exocrine cells [Yang et al., 
2012]. As the pancreas matures, Pdx-1 expression becomes restricted to β-cells. Pdx-1 
maintains normal pancreatic function by regulating insulin, glucose transporter 2 (Glut2) 
and glucokinase (GCK) gene expression in the promoter region of β-cells. In the last 
decade, researchers have invested a lot of time in determining the importance of Pdx-1 
expression. Genetic studies on homozygous and heterozygous Pdx-1 mutated mice 
have linked Pdx-1 to pancreatic agenesis and impaired glucose tolerance, respectively 
[Fujimoto et al., 2010; Claiborn et al., 2010]. There are many stimuli which stimulate 
Pdx-1 expression in β-cells such as glucose, oxidative stress and free fatty acids 
[Ardestani et al., 2011]. Acute exposure of β-cells to glucose translocates Pdx-1 to the 
nucleus, inducing β-cell proliferation and insulin secretion [Ardestani et al., 2011]. 
Prolonged exposure of β-cells to hyperglycemia exhibited increased DNA methylation 
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followed by a reduction in Pdx-1 expression [Yang et al., 2012]. This impairs β-cell 
function and insulin secretion ultimately leading to β-cell death via apoptosis [Ardestani 
et al., 2011; Yang et al., 2012]. Pdx-1 expression is regulated by post-translational 
modification and cellular localization [Ardestani et al., 2011]. 
 
Insulin resistance has detrimental effects on Pdx-1 expression and activity. During 
insulin resistance, the inhibitory effect of insulin on GSK-3β and FoxO1 is lifted, 
reducing β-cell proliferation. GSK-3β negatively regulates β-cell mass and function by 
phosphorylating Pdx-1 on specific serine (Ser61 and Ser66) residues, marking them for 
proteasomal degradation, thus, reducing its half life [Fujimoto and Polonsky, 2009]. 
FoxO1 blocks Pdx-1 expression via translocation, moving Pdx-1 from the nucleus to the 
cytosol [Fujimoto and Polonsky, 2009]. GSK-3β and FoxO1 enhances β-cell death at a 
protein and transcriptional level, respectively [Fujimoto and Polonsky, 2009]. 
 
1.6.1.4.2 Maf A 
 
Musculoaponeurotic fibrosarcoma homolog A is a transcription factor of the basic 
leucine zipper (bzip) family [Kannan et al., 2012]. Members of the MAF family are 
divided up into two classes, “large” (Maf A, Maf B and c-Maf) and “small” (Maf F, Maf G 
and Maf K) MAF proteins, depending on their molecular size [Nishimura et al., 2009]. 
Large Maf proteins consist of an additional amino-terminal transactivation domain (TAD) 
and binds to two palindromic sequences on the insulin promoter region called Maf 
responsive elements (MAREs), stimulating the transcription of target genes [Nishimura 
et al., 2009; Rocques et al., 2007]. Maf A is a unique transcription factor expressed 
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during late pancreatic development and restricted to pancreatic β-cells [Hunter et al., 
2011]. The main role of Maf A is to maintain normal blood glucose levels in the body by 
regulating insulin gene expression [Jorgensen et al., 2007; Kataoka et al., 2002]. 
A study done by Nishimura and colleagues on Maf A deficient mice have shown a 
gradual reduction in the β to α cell ratio with age even though postnatal β-cell levels 
were normal [Nishimura et al., 2009]. These animals were glucose intolerant and 
developed diabetes; emphasizing the importance of Maf A as a regulator of β-cell 
maturation [Nishimura et al., 2009]. Zhao reported the transcriptional rate of insulin to 
be moderate when Maf A was expressed in the β-cell alone, but in accordance with 
Pdx-1, the synergistic action enhanced insulin promoter activity [Zhao et al., 2005].  
1.6.1.5 Treatment: type 1 diabetes 
T1D occurs as a result of autoimmunity against pancreatic β-cells, ultimately leading to 
β-cell destruction. Therefore, therapeutic strategies prolonging or preventing β-cell 
dysfunction would serve to be beneficial in treating T1D patients. Annihilation of β-cells 
by the immune system reduces the amount of endogenous insulin secreted into 
circulation. As a result of the body not producing sufficient insulin to sustain normal 
glucose homeostasis, these patients are required to take alternative sources of insulin 
for life. Patients are primarily treated with insulin injections taken on a regular basis. 
There are several other modes of administrating insulin which include external insulin 
pumps, insulin inhalers and internal insulin pumps. These patients could also undergo 
more invasive treatments such as gene therapy, pancreatic islet transplantation and 
whole pancreas transplantation.  Other treatment options available are β-cell replication, 
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reprogramming of mature β-cells and stem cell transplantation. These procedures are 
very expensive and is therefore not a common option in developing countries.   
1.6.1.6 The Streptozotocin-model of type 1 diabetes. 
Streptozotocin (STZ) is a glucosamine compound which contains a very reactive 
nitrosourea group [Wei et al., 2003; Arora et al., 2009]. This compound, derived from a 
soil microbe called Streptomyces achromogenes, was initially used as an antibiotic and 
later added to medication for the treatment of pancreatic cancer, specifically cancer of 
the islets of Langerhans [Motyl and McCabe, 2009]. Streptozotocin has a glucose 
moiety which is easily transported into pancreatic β-cells via glucose transporter 2, 
where it exerts its toxic effects by damaging DNA [Wei et al., 2003; Motyl and McCabe, 
2009]. This leads to β-cell dysfunction, hypoinsulinemia and hyperglycemia; all 
characteristics associated with diabetes [Motyl and McCabe, 2009].  When inducing a 
T1D model, one should keep in mind that STZ performs at its best when stabilized 
[Motyl and McCabe, 2009]. STZ is stable at a pH of approximately 4 and it is for this 
reason that STZ is prepared in a citrate buffer with a pH of 4.5; thus enhancing stability 
and inducing diabetes [Motyl and McCabe, 2009].  The severity of type 1 diabetes 
depends on the species of the animal, age and the amount of STZ administrated 
intravenously or intraperitoneally [Arora et al., 2009]. For example, a single dose of STZ 
is effective in inducing T1D in rat models while multiple low doses of STZ serves to be 
most effective in inducing T1D in mice models [Motyl and McCabe, 2009].  
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1.6.2 Type 2 Diabetes 
Type 2 Diabetes, formerly accepted as adult onset diabetes, is a multi-factorial disorder 
that accounts for 90-95% of all diabetic cases worldwide, making it the most common 
type of diabetes known [Stumvoll et al., 2005]. The pathological sequence for T2D is 
complex and entails many risk factors promoting its onset and development [Leahy, 
2005]. T2D occurs as a result of insufficient insulin production by pancreatic β-cells or 
reduced insulin action at target tissues. Reports have shown insulin resistance to be 
present prior to β-cell dysfunction in type 2 diabetic individuals maintaining normal blood 
glucose levels [Leahy, 2005]. The progression from normoglycemia to glucose 
intolerance occurs as a result of reduced β-cell function rather than a spike in insulin 
resistance [Leahy, 2005]. Beta cell function varies and is dependent on the degree of 
insulin sensitivity [Leahy, 2005]. A reduction in insulin action stimulates the glucose 
homeostatic system to increase β-cell function by increasing β-cell mass [Stumvoll et 
al., 2005]. This compensatory mechanism gradually loses its ability to produce the 
additional insulin needed to overcome insulin resistance, impairing the responsiveness 
of β-cells to glucose [Leahy, 2005]. As blood glucose levels rise, hyperglycemia 
promotes β-cell dysfunction by altering various metabolic pathways, enzymes and 
genes (impairing proinsulin transcription) important for proper functioning. 
Hyperglycemia deteriorates β-cells even further by stimulating the production of malonyl 
CoA (in skeletal muscle and the liver) that inhibits fatty acid oxidation, thus, favouring 
lipotoxicity [Leahy, 2005]. An excess of free fatty acids promote β-cell dysfunction and 
death by producing fatty acid metabolites such as ceramides and oxidative stress 
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precursors [Leahy, 2005]. In addition, the generation of amyloids contribute to defective 
β-cell function [Leahy, 2005]. 
1.6.2.1 The role of obesity in the development of insulin resistance 
Obesity is a disease which affects individuals of all ages and both sexes, globally 
[Aballay et al., 2013]. This disease occurs as a result of excessive fat accumulation due 
to a chronic caloric imbalance, impairing an individual’s health status [Pulgarόn, 2013]. 
Obesity is assessed and defined by the body mass index (BMI) as being ≥ 30 kg/m2 
according to the World Health Organization [2013]. The BMI is calculated based on the 
weight in kilograms divided by the square of the height in meters [WHO, 2013].  
Obesity has become a major public health problem prevailing in both developing and 
developed countries [Aballay, 2009]. This problem is further exacerbated by an increase 
in urbanization, changes in eating habits and a reduction in physical activity. According 
to WHO, more than 1,4 billion adults worldwide are overweight and of these individuals, 
over 200 million men and nearly 300 million women were obese [WHO, 2013]. This 
organization also predicted that these numbers would double by the year 2015 
emphasizing the importance of treatment [Nguyen et al., 2010].  
Obesity has a tremendous impact on society, drawing attention towards the economic 
and health sector.  In terms of the economy, obesity exerts an enormous financial strain 
on the economic budget as more finances are pushed into treating obese related 
morbidities and secondary diseases [Dodd, 2008]. With regards to the health sector, 
obesity affects an individual’s quality of life as it is associated with a variety of co-
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morbidities such as type 2 diabetes (T2D), cardiovascular disease, sleep apnea and an 
array of cancers [Stumbo et al., 2005; Sahani et al., 2010]. These individuals exhibit a 
strong correlation between obesity and the development of the metabolic syndrome 
which encompasses dyslipidemia, hypertension, insulin resistance and proinflammation 
[Chen and Morris, 2007].  
The section that follows will explain the link between obesity and insulin resistance as 
well as the manifestation of T2D. Current therapeutic strategies will also be discussed.  
1.6.2.1.1 The link between obesity and adipose dysfunction 
As previously stated, obesity stems from a caloric imbalance which arises when energy 
intake exceeds energy expenditure. The human body makes use of two main types of 
energy substrates to maintain survival, namely, glucose (carbohydrates) and free fatty 
acids (lipids). In this section, we will be focusing on triacylglycerol stores, circulating free 
fatty acids and the origin of insulin resistance.   
Adipose tissues are the largest and main lipid storage depots in our body, playing a 
vitally important role in energy metabolism [Goossens, 2008]. These tissues are made 
up of many adipocytes which produce and secrete numerous adipokines, and cytokines 
in response to various stimuli. During the postprandial state, adipocytes regulate the 
influx of dietary fats via a buffering action which suppresses the release of free fatty 
acids into circulation and increases the activity of lipoprotein lipase, thus enhancing 
triacylglycerol clearance [Goossens, 2008]. Adipocytes of obese individuals are 
enlarged as a result of adipose tissue being overloaded with triacylglycerol (TAG) 
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[Goossens, 2008]. During the fed state these individuals are exposed to an additional 
amount of fatty acids that cannot be cleared effectively due to adipocytes reaching its 
optimum storage capacity [Goossens, 2008]. As a result, the number of fatty acids and 
triacylglycerol entering circulation increases. Non-adipose tissue such as the liver and 
muscle would try and mop up excess substrates in circulation by oxidizing fats, thus 
preventing any adverse metabolic effects [Goossens, 2008]. Over time these tissues 
lose the ability to oxidize fats efficiently leading to the accumulation of lipids which are 
associated with conditions (glucose intolerance, hyperlipidemia and hyperinsulinemia) 
related to insulin resistance. Insulin resistance is defined as a state of reduced 
responsiveness of target tissues to normal circulating levels of insulin [Sesti, 2006]. 
It should be noted that adipose tissue not only serve as the main TAG store in the 
human body but also secrete numerous adipokines and cytokines which affect insulin 
sensitivity [Kahn and Flier, 2000]. The role free fatty acids, adipokines and cytokines 
play in insulin resistance will be further discussed below.    
1.6.2.1.2 Fatty acid induced insulin resistance 
Free fatty acids play an extremely important role in insulin resistance of obese or 
overweight individuals by inducing hyperinsulinemia; impairing insulin action and 
impairing glucose metabolism [Golay and Ybarra, 2005]. Two mechanisms concerning 
the induction of insulin resistance, via the abundance of free fatty acids in circulation, 
has been postulated by Randle and Shulman [Randle et al., 1963; Shulman, 2000]. 
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In the 1960’s, Randle and colleagues proposed that elevated plasma FFA levels inhibit 
glucose oxidation by negatively influencing key enzymes in the glycolytic pathway of 
isolated rat heart muscles, and diaphragms [Randle et al., 1963]. The theory behind 
Randle’s hypothesis states that an increase in lipid oxidation raises the mitochondrial 
acetyl-CoA/CoA and NADH/NAD+ ratios to a point where these factors are capable of 
inhibiting the enzyme pyruvate dehydrogenase [Kovacs and Stumvoll, 2005]. The cell 
would try and get rid of excess acetyl CoA by diverting it into the Krebs cycle, increasing 
the concentration of citrate. As citrate levels increase, phosphofructokinase activity is 
inhibited to prevent the accumulation of acetyl CoA by blocking the production of 
pyruvate [Kovacs and Stumvoll, 2005]. The inactivation of phosphofructokinase causes 
the level of glucose-6-phosphate to rise to an extent where it inhibits hexokinase II 
activity, thus reducing glucose uptake and ultimately impairing glucose homeostasis 
[Kovacs and Stumvoll, 2005]. There have been many conflicts with Randle’s theory, 
which has been rectified by several authors investigating the link between lipid 
accumulation and the inhibition of insulin stimulated glucose uptake at a cellular level 
[Golay and Ybarra, 2005].  These studies have shown an influx of lipids to be 
associated with insulin resistance by inhibiting glucose transport and/or phosphorylation 
[Kovacs and Stumvoll, 2005]. This subsequently decreases the rate of glucose oxidation 
and storage by inhibiting glycogen synthase.      
An investigation done by Shulman confirmed that high plasma fatty acid levels induce 
insulin resistance via the inhibition of glucose transport [Shulman, 2000]. Under normal 
physiological conditions, insulin mediates tyrosine phosphorylation of IRS which 
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stimulates PI-3K activation [Kovacs and Stumvoll, 2005; Shulman, 2000]. As discussed 
in section 1.5.2, active PI-3K triggers a cascade of events, promoting the translocation 
of GLUT to the membrane. Shulman hypothesized that the skeletal muscle of obese 
individuals are exposed to an abundance of lipid metabolites, such as fatty acyl CoA, 
ceramides and diacylglycerol, which negatively affect glucose uptake [Shulman, 2000]. 
A concentration hike in lipid metabolites sets off a range of adverse effects, triggering 
the serine/threonine kinase cascade by increasing the activity of protein kinase C θ 
(PKC-θ) [Kovacs and Stumvoll, 2005; Shulman, 2000 ]. Serine phosphorylation by PKC-
θ sterically hinders IRS-1 tyrosine phosphorylation, reducing the activity of PI-3K by 50 
% ultimately reducing the translocation of GLUT 4 to the membrane [Petersen and 
Shulman, 2006]. 
1.6.2.2 The link between adipocyte secretions and insulin resistance 
Adipocytes secrete several bioactive compounds which play a crucial role in regulating 
blood pressure, lipid metabolism, inflammation and glucose metabolism [Rabe et al., 
2008]. These secretory compounds include adipokines and cytokines. In this section, 
the influence of certain adipokines and cytokines on insulin resistance, will be 
discussed.    
1.6.2.2.1 Adipokines 
Leptin is a 16 kD hormone produced by the ob gene, playing an essential role in nutrient 
homeostasis [Fantuzzi, 2005; Elmquist, 2001]. Principally, leptin exerts its metabolic 
action in the hypothalamic region of the central nervous system (CNS) [Kahn and Flier, 
2000].  Once leptin signals the CNS, the autonomic system (ANS) and the 
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neuroendocrine pathway are immediately alerted. In response, these pathways regulate 
food intake, energy storage, blood pressure and energy expenditure by modulating 
various metabolic processes in peripheral tissue, thus improving insulin sensitivity 
[Rabe et al., 2008; Elmquist, 2001]. Aside from the ability of leptin to act via the CNS, it 
is capable of directly stimulating the liver, skeletal muscle and pancreatic β-cells [Kahn 
and Flier, 2000]. 
The adipo-insular axis is a feedback loop established between the adipose tissue and 
the pancreatic β-cell [Rabe et al., 2008; Kieffer and Habener, 2000]. This axis is fully 
operational when body weight increases, which correlates positively with leptin levels. 
Leptin protects β-cells from detrimental effects associated with lipid accumulation by 
reducing lipid levels through fatty acid oxidation, thus improving β-cell function 
[Friedman, 2002]. In turn, viable β-cells secrete insulin which promotes both leptin 
biosynthesis and secretion by adipocytes. In summary, leptin promotes insulin 
sensitivity in all peripheral tissues. The theory behind this axis is that an accumulation of 
fatty acids in adipose tissue causes an increase in leptin levels, which protects β-cells 
from deleterious effects associated with lipid accumulation [Rabe et al., 2008; Kieffer 
and Habener, 2000 ]. 
The link between leptin and insulin resistance was made evident in studies done on 
leptin deficient (ob/ob) mice [Friedman, 2002]. These ob/ob mice exhibited immune 
defects, decreased body temperature, infertility, hyperphagia, obesity, decreased 
energy expenditure, diabetes and hypercortisolemia which were associated with 
abnormalities in metabolic and/or endocrine pathways. Leptin treatment reversed all 
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adverse effects by decreasing the intracellular lipid content in all tissues [Friedman, 
2002].  
The concept of leptin resistance arose from obese individuals who portrayed high leptin 
levels without suppressing appetite or inducing weight loss [Kahn and Flier, 2000]. This 
occurs as a result of lipid accumulation within target tissues limiting insulin action, thus 
causing insulin resistance [Friedman, 2002]. As a result pancreatic β-cells would 
produce more insulin to compensate for the resistance leading to hyperinsulinemia. 
Hyperinsulinemia is thought to promote leptin synthesis and secretion via adipose 
tissue, further enhancing leptin resistance.      
Adiponectin is an anti-inflammatory cytokine abundantly secreted by adipose tissue. As 
a result of adipocytes being the main source of adiponectin, one would expect serum 
adiponectin levels to rise with an increase in body weight but this is not the case 
[Fantuzzi, 2005]. Studies have shown adiponectin levels to be reduced in obese and 
insulin resistant subjects, while individuals suffering from anorexia expressed high 
levels of adiponectin [Fantuzzi, 2005]. In obese subjects, the administration of 
adiponectin improved whole body insulin sensitivity by targeting various tissues. In the 
skeletal muscle, adiponectin increases glucose uptake and fatty acid oxidation, while 
reducing hepatic glucose production [Rabe et al., 2008].  
These insulin sensitizing effects are initiated when adiponectin binds to specific 
adiponectin receptors, adiponectin receptor1 (AdipoR1) and adiponectin receptor 2 
(AdipoR2). The expression of AdipoR1 and AdipoR2 has been shown to be linked to the 
Stellenbosch University  https://scholar.sun.ac.za
42 
 
activation of AMPK and peroxisome proliferator-activated receptor-α (PPAR-α), 
respectively [Rabe et al., 2008]. Yamauchi et al. reported that a disruption in AdipoR1 
and AdipoR2 correlated with an increase in insulin resistance as a result of a reduction 
in adiponectin binding and action [Yamauchi et al., 2007]. Many human studies have 
shown adiponectin levels to be negatively related to type 2 diabetes, obesity and insulin 
resistance [Rabe et al., 2008]. Therefore, boosting adiponectin levels or adiponectin 
receptor function would be beneficial in treating all negative components associated 
with the establishment of T2D.  
1.6.2.2.2 Cytokines 
Obesity is a chronic low-grade inflammatory state that is linked to the expression of 
various pro-inflammatory cytokines [Fantuzzi, 2005]. Numerous studies have reported a 
correlation between pro-inflammatory cytokines and clinical features associated with the 
metabolic syndrome such as BMI and insulin resistance [Sesti, 2006].  There are many 
other factors which promote the expression of pro-inflammatory cytokines involved in 
the manifestation of obesity-induced insulin resistance. These factors include oxidative 
stress that is generated as a result of lipid accumulation [Styskal et al., 2012]. Oxidative 
stress can modulate insulin action either by targeting the insulin pathway directly or by 
stimulating the activation of proteins involved in inflammation. In this section we will be 
focusing on TNF-α and IL-6. 
A study done by Hotamisligil and colleagues (1993) reported that TNF-α mediates 
insulin resistance in obese rodent models [Hotamisligil et al., 1993]. This notion was 
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deduced when they observed high levels of TNF-α messenger RNA being expressed by 
adipose tissues which were further enhanced in adipose tissue of obese and diabetic 
rodent models. In addition, several other studies on TNF-α-null and TNF-α receptor-null 
mice support this hypothesis [Chen, 2006]. TNF-α signaling can directly alter insulin 
action by phosphorylating specific serine residues on the insulin receptor or insulin 
receptor substrate 1, thus inhibiting insulin signaling, giving rise to insulin resistance 
[Fantuzzi, 2005]. Other mechanisms by which TNF-α induces insulin resistance is by 
downregulating adiponectin expression, increasing IL-6 production, stimulating lipolysis 
and increasing the release of free fatty acids from adipocytes [Goossens, 2008]. 
Despite the correlation between TNF-α and insulin resistance, TNF-α neutralizing 
treatments have not shown improved insulin sensitivity in diabetic patients [Fantuzzi, 
2005].   Instead, these patients were exposed to an increased risk of contracting 
opportunistic infections. 
Interleukin 6 is a multifunctional cytokine which plays an important role in a wide range 
of processes [Simpson et al., 1997].  For this review, we will only be focusing on the link 
which exists between IL-6 and insulin resistance. In the presence of obesity, an 
overload of nutrients in adipose tissue upregulates the release of free fatty acids and 
pro-inflammatory cytokines; activating resident macrophages [Chen, 2006].  Activated 
macrophages secrete TNF-α and IL-6 which recruit additional macrophages into 
adipocytes [Chen, 2006]. Increased levels of circulating TNF-α and IL-6 cause insulin 
resistance in adipocytes through several distinct mechanisms which include c-Jun N-
terminal kinase 1 (JNK1) mediated serine phosphorylation and inactivation of IRS-1, IκB 
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kinase (IKK)-mediated nuclear factor-κB (NF-κB) activation, and induction of suppressor 
of cytokine signaling 3 (SOCS-3) [Chen, 2006; Rabe et al., 2008]. Studies have shown 
IL-6 levels to be high in obese and insulin resistant subjects with an increase in hepatic 
glucose production [Rabe et al., 2008]. A reduction in weight has positive effects on 
insulin sensitivity amongst others, by lowering IL-6 expression. 
1.6.2.3 Treatment: Type 2 diabetes 
Type 2 diabetes is a disease which attracts a lot of attention and is constantly 
researched for the establishment of new anti-diabetic drugs which are safe and 
effective. Interest in the treatment of T2D patients arose as a result of these patients not 
being able to control glycaemia sufficiently in the presence of anti-diabetic drugs [Bailey, 
1999]. Below is a flow chart indicating various treatment options available as well as a 
table containing a list of anti-diabetic drugs with their specific functions [Bailey, 1999; 
























Figure 10: Type 2 diabetic treatment system [Bailey, 1999] 
Initially, T2D patients undergo lifestyle changes (increased physical activity, 
healthier eating patterns and a reduction in weight). This option serves to be 
ineffective in approximately four-fifths of newly diagnosed patients causing them 
to move to the next treatment level [Bailey, 1999]. If a patient cannot maintain 
glycaemic control after being treated with an oral agent, be that in a combination 








Diet, exercise and weight control 
Monotherapy with an oral agent 
       Combination therapy with two different classes 
of oral agents 
        Insulin 
Insulin plus an oral agent 
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Table 3: List of anti-diabetic drugs [Bailey, 1999; Shah et al, 2013; Doyle and 
Egan, 2007].  
Thiazolidinedione is one of the anti-diabetic drugs removed from the market as a result 
of this drug promoting liver toxicity [Tolman and Chandramouli, 2003]    
 
1.7 Skeletal muscle metabolism 
Skeletal muscle is the most abundant tissue within the human body and is accountable 
for 40 percent of body weight [Andres et al., 1956]. This tissue demands energy in the 
form of adenosine triphosphate (ATP) for contractile purposes and to sustain proper 
cellular function. Skeletal muscle utilize numerous substrates depending on their 
exposure to specific stressors. At rest, skeletal muscle prefers using fatty acids as their 
main energy source which is followed by glucose [El-Bacha et al., 2010]. During hypoxia 
or intense physical activity for a long duration of time, skeletal muscle switches from 
fatty acid metabolism to glucose metabolism [Kessler and Friedman, 1998; El-Bacha et 
al., 2010]. A switch in metabolism stems from the fact that glucose oxidation results in a 
higher production of energy (in the form of high energy phosphate bonds) when oxygen 
Agent Action 
Sulfonylureas eg. Glipizide Increase insulin secretion by stimulating β-
cells 
Biguanides  eg. Metformin Improve insulin sensitivity in peripheral tissue 
Alpha-glucoside inhibitors eg. Acarbose Slow carbohydrate digestion 
Thiazolidinediones eg. Avandia Improve insulin sensitivity in peripheral tissue 
Glucagon-like peptide-1 (GLP-1) 
analogues 
Increase insulin synthesis and secretion by 
stimulating β-cells 
Dipeptidyl peptidase 4 (DPP4) inhibitors Inhibit the breakdown of GLP-1 
Insulin Decrease hepatic glucose output and increase 
peripheral glucose utilization 
Bariatric surgery (Weight loss surgery) Alters the digestive system by restricting food 
intake. Mainly focusing on the stomach and/or 
intestine. 
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is scarce compared to fatty acid oxidation [Kessler and Friedman, 1998]. In this section 
of the review we will focus on fatty acid and glucose metabolism. 
As stated above, fatty acids are the main source of energy in skeletal muscle during rest 
and mild-intensity exercise. As exercise intensity increases, glucose oxidation 
suppresses fatty acid oxidation [El-Bacha et al., 2010]. 
1.7.1 Fatty acid metabolism 
The amount of fatty acids taken up by myocytes depends on the rate of lipolysis within 
adipose tissue. The lipolytic activity of adipocytes is enhanced when the body is 
exposed to metabolic stresses such as fasting or diabetes. These states ultimately lead 
to the accumulation of free fatty acids in blood, thus increasing fatty acid uptake and 
oxidation in peripheral tissue. Under normal conditions, insulin stimulates the clearance 
of circulating free fatty acids by inhibiting lipolysis and fatty acid β-oxidation.  
Circulating free fatty acids enter the cell via fatty acid transporters or diffusion [Koonen 
et al., 2005]. Once inside the cell, fatty acids are surrounded by acyl-CoA synthetase, a 
cytosolic enzyme which adds an acyl-CoA group to fatty acids [Finn and Dice, 2006]. 
Long fatty acyl-CoA molecules are able to cross the outer mitochondrial membrane but 
not the inner membrane, therefore, requiring a transportation or shuttling mechanism 
[Jaswal et al., 2011]. Carnitine palmitoyl transferase I mediates the movement of fatty 
acids into the mitochondrial matrix by replacing the CoA group with carnitine. Inside the 
matrix, fatty acyl carnitine is converted back into fatty acyl CoA, with the help of 
carnitine palmitoyl transferase II, which is localized on the inner mitochondrial 
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membrane [Jaswal et al., 2011]. Carnitine released from the fatty acyl molecule moves 
back to the outer mitochondrial membrane where it is reused. 
In the mitochondrial matrix fatty acyl CoA undergoes β-oxidation. Mitochondrial β-
oxidation is a step-wise reaction that repetitively breaks down long chain fatty acyl CoA 
to form acetyl CoA molecules. Acetyl CoA undergoes a whole range of reactions 
eventually producing ATP in the Krebs cycle. The number of acetyl-CoA molecules 
produced depends on the fatty acid carbon length being oxidized. The first step of fatty 
acid oxidation is the dehydrogenation of fatty acyl CoA [Kim and Battaile, 2002]. In this 
reaction, acyl-CoA dehydrogenase (ACD) catalyzes the conversion of fatty acyl CoA to 
trans 2 enoyl CoA and removes protons from fatty acyl CoA which are transferred to a 
FAD cofactor, yielding FADH2 [Schultz, 2008]. There are four ACDs involved in fatty 
acid β-oxidation, namely, short chain (SCAD), medium-chain (MCAD), long-chain 
(LCAD) and very long chain (VLCAD) ACD [Kim and Battaile, 2002]. The acyl chain 
length of each ACD reflects their preferred substrate specificity, ensuring complete 
degradation of all fatty acids [Lea et al., 2000; Schultz, 2008]. The second step in the β-
oxidation cycle is a hydration reaction [Kim and Battaile, 2002]. The enzyme enoyl CoA 
hydratase together with a water molecule (H2O) hydrates 2-trans-enoyl CoA to form L-3-
hydroxy acyl COA [Schultz, 2008]. The third step is a dehydrogenation reaction 
catalyzed by L-3-hydroxy acyl COA dehydrogenase, with nicotinamide adenine 
dinucleotide (NAD+) as the cofactor [Kim and Battaile, 2002]. The hydroxyl group of L-
hydroxy acyl CoA is oxidized to a keto group, producing 3- ketoacyl CoA and NADH 
[Kim and Battaile, 2002]. In the final step of β-oxidation, 3-ketoacyl CoA is cleaved by 
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thiolase to yield acetyl CoA and an acyl CoA molecule [Schultz, 2008]. Every cycle of β-
oxidation sequentially shortens fatty acyl CoA molecules by two carbon atoms, 
producing one acetyl CoA as well as NADH and FADH2 [Jaswal et al., 2011; Fillmore 
and Lopaschuk, 2013]. Acetyl CoA can either enter the Krebs cycle or be used in the 
production of ketone bodies [Frick et al., 2008].  
1.7.2 Glucose metabolism 
Insulin stimulated GLUT 4 translocation to the plasma membrane promotes glucose 
uptake, leading to the accumulation of glucose molecules within the cell [Huang et al., 
2005]. Glucose transporter 4 is the insulin-responsive protein responsible for the 
transport of glucose across the plasma membrane into myocytes. Glucose uptake is 
triggered by insulin which is stimulated by high blood glucose levels. Insulin promotes 
GLUT 4 translocation to the membrane by activating PKB/Akt [Wang et al., 1999].  In 
diabetic patients, glucose uptake in skeletal muscle is drastically reduced as a result of 
insulin resistance or insufficient insulin secretion [Wilcox, 2005]. 
Glucose accumulation in skeletal muscle can either be stored as glycogen or enter 
glycolysis. The glycolytic pathway consists of three stages: the priming, splitting and 
energy producing stage (figure 11) [Berg et al., 2002; Pelicano et al., 2006]. During the 
priming stage, glucose is converted to fructose 1,6 bisphosphate via three reactions, 
catalyzed by various enzymes [Berg et al., 2002; Pelicano et al., 2006]. These reactions 
trap and destabilize glucose by the addition of two phosphoryl groups from ATP 
molecules [Berg et al., 2002]. In the splitting stage, fructose 1,6 bisphosphate is readily 
cleaved into two three-carbon fragments by aldolase, producing glyceraldehyde 3-
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phosphate (GAP) and dihydroxyacetone phosphate (DHAP) [Berg et al., 2002]. GAP 
and DHAP are isomers, which are easily converted to the one or other with the help of 
triosephosphate isomerase [Berg et al., 2002; Pelicano et al., 2006]. In the presence of 
glycolysis, DHAP would be converted to GAP, rendering two molecules of GAP for 
every glucose molecule broken down [Berg et al., 2002]. The energy producing stage is 
a five step reaction converting two GAP molecules to pyruvate [Berg et al., 2002; 
Pelicano et al., 2006]. This stage produces four ATPs from a series of oxidative 
phosphorylation reactions [Berg et al., 2002]. The final glycolytic product, pyruvate, can 




























Figure 11: glycolytic pathway [Pelicano et al., 2006] 
Each glucose molecule produces two pyruvate molecules via the stimulation of 
several enzymes. In step 1, glucose is phosphorylated to glucose-6-phosphate 
with the help of hexokinase. Glycogen can serve as a supplementary source of 
glucose-6-phosphate in the presence of metabolic stress, such as fasting. Every 
enzyme in the glycolytic pathway is tightly regulated.  ATP, adenosine 
triphosphate; ADP, adenosine diphosphate; PK, Pyruvate kinase; PGM, phospho 
glycerate mutase; PGK, phospho glycerate kinase; GAPDH, glyceraldehyde 
phosphate dehydrogenase; TPI, triose phosphate; PFK, phosphofructokinase; 
PGI, phosphohexose isomerase; HK, hexokinase. 
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1.7.3 Oxidation of Acetyl CoA 
The production of acetyl CoA from the oxidative cleavage of fatty acids or the 
decarboxylation of pyruvate, made available by glycolysis, is completely oxidized by the 
Krebs cycle and electron transport chain [Zubay, 2000]. 
1.7.3.1 Krebs cycle  
The Krebs cycle, also known as the tricarboxylic acid or citric acid cycle, is the final 
catabolic pathway for the oxidation of fuel molecules and occupies a central position in 
metabolism [Koubaa et al, 2013; Hagopian et al., 2004]. The cycle is composed of a 
variety of enzymes and metabolites, which are important for the progression of many 
other pathways; therefore, its position is of utmost significance [Hagopian et al., 2004].  
Acetyl CoA is the key substrate initiating the cyclic process. The Krebs cycle is an eight 
step reaction which generates carbon dioxide molecules and reducing equivalents, 
NADH and FADH2 [Hagopian et al., 2004]. The cycle begins when a two carbon acetyl 
CoA molecule binds to oxaloacetate to form a six carbon molecule, citrate. The addition 
of a single water molecule is essential for the release of the CoA subunit from acetyl 
CoA. Citrate undergoes two consecutive decarboxylation events and several oxidative 
reactions, ultimately generating the four carbon compound, oxaloacetate [Zubay, 2000]. 
Each molecule of acetyl CoA produces two carbon dioxide molecules, one FADH2 
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1.7.3.2 Electron transport chain  
Reducing equivalents produced by β-oxidation and the Krebs cycle transport energy to 
the mitochondrial electron transport chain (ETC) [Rossignol and Frye, 2012]. The ETC 
is the final respiratory stage, consisting of a series of oxidative phosphorylation 
reactions for ATP generation [Rossignol and Frye, 2012]. This energy is produced by 
five multimeric complexes located on the inner mitochondrial membrane [Bayir and 
Kagan, 2008]. Once NADH and FADH2 molecules release hydrogen atoms to 
complexes I and II, respectively, an electrochemical gradient is established. Electrons 
discharged by reducing equivalents moves down the chain of protein complexes with 
the help of two electron carriers, co-enzyme Q10 and cytochrome C [Rossignol and 
Frye, 2012]. In complexes I, III and IV, electrons give up some of their energy to extrude 
protons out of the mitochondrial matrix into the intermembrane space via active 
transport [Bayir and Kagan, 2008]. The movement of electrons generates an alkaline 
matrix and an acidic intermembrane space [Bayir and Kagan, 2008]. Electrons finally 
reach complex IV, where they bind to protons and an oxygen molecule to form water 
[Swerdlow, 2012]. Protons re-enter the matrix through complex V, a non-ETC enzyme, 
providing enough energy to synthesize ATP from ADP, which is utilized as energy by 






















Figure 12: Electron transport chain [Swerdlow, 2012]  
NADH and FADH2 molecules donate electrons to the electron transport chain. The 
movement of electrons down the chain produces enough energy to transport 
protons across the mitochondrial membrane into the intermembrane space. 
Electrons bind to oxygen, the final electron receptor, and forms water. Protons 
move back into the mitochondrial matrix through ATP synthase, producing ATP.  
FADH2, flavin adenine dinucleotide; NADH, nicotinamide adenine dinucleotide; 
CoQ, Coenzyme Q (ubiquinone); ADP, Adenosine diphosphate; ATP, Adenosine 
triphosphate; H+, proton. 
 
 




Materials and Methods 
 
 
2.1. Animal Care 
Male Wistar rats were used in this study. These rats were age and weight matched at 
the onset of the experiment. All animals were housed at the University of Stellenbosch 
Central Research Facility, which provided a simulated environment of the animals’ 
natural habitat, exposing them to a temperature controlled room (22 °C - 24 °C) and a 
12-hour light/dark cycle. Animals had free access to water and food for the duration of 
the experiment. All animals were fed normal rat chow, unless otherwise stated/ 
specified, and specific groups in both diabetic models were treated with Buchu water. 
The project was approved by the Ethics committee of the University of Stellenbosch 
(Faculty of Health Sciences – protocol number SU-ACUM11-00003) and conforms to 
the principals revised in the South African National Standard for the Care and Use of 
Animals for Scientific Purposes (South African Bureau of Standards, SANS 10386, 
2008). 
2.2. The administration procedure of Buchu (Agathosma) 
1.3L of the watery extract of Buchu, provided by the company Cape Kingdom, was 
mixed with tap water to make up a volume of 5000 ml. This mixture replaced water 
given to specific animal groups. The dosage of Buchu was calculated based on the 
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average weight of a 70 kg individual ingesting 350 ml of undiluted Buchu water/day. 
Equivalent surface area dose expressed as mg/kg was used for calculation of the 
dosage using the assumptions and constants of the paper by Freireich et al. 1996. For 
the initial estimations, it was assumed that a rat will drink 30ml of water per day. 
2.3. Animal models 
2.3.1. Streptozotocin-induced type 1 diabetes rat model 
In this model, a total of 50 animals were used and the experiment lasted for a period of 
14 weeks. Animals weighing approximately 250 g were randomly divided into two main 
groups: a control (n=20) and diabetic (n=30) group. All animals allocated to the diabetic 
group were subjected to a once off intra-peritoneal STZ injection of 40 mg/kg (dissolved 
in a citrate buffer; pH 4.5) and blood glucose levels were determined after 24 hours, and 
at 1 week. After 1 week, animals that have been injected with STZ whose blood glucose 
levels normalized spontaneously, were excluded from the experimental group. The main 
purpose for using STZ at this concentration was to induce a type 1 diabetic model, 
ensuring ablation of approximately 50% of pancreatic beta cells. This brings about high 
blood glucose levels ranging between 10 and 20 mmol/L but the animals still produce 
endogenous insulin. A commercial glucometer was used to monitor blood glucose levels 
by collecting blood from a single tail prick. For a diagrammatic interpretation of the 
divisional state of all animals involved in the STZ- induced type 1 diabetic model refer to 
figure 13.  The food and water intake of the animals were monitored for a period of a 
week and 20 days, respectively, 3 weeks after the start of the experiment. The amount 
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of food consumed was measured by the following equation: Food consumed per day (g) 













Figure 13: Schematic representation of the division of type 1 diabetic animals 
Buchu day 1: The administration of Buchu water from the start of the experiment 
Buchu week 3: The administration of Buchu water 3 weeks after the initiation of the experiment  
 
Intraperitoneal glucose tolerance tests (IPGTT) were performed on all animals to 
determine the effect of Buchu water on whole-body insulin sensitivity. This was done by 
fasting animals overnight a week (week 13) prior to the time of sacrifice. Animals were 
anaesthetized (< 50 mg/kg pentobarbital) and fasting blood (1 ml) was collected from 
        Male Wistar rats 
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       (~250 g) 
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       Untreated 




       Control + Buchu day 1 




       Untreated 




       STZ + Buchu day 1 
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n= 20 
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the carotid artery for the determination of insulin levels (Coat-A-Count®) 
Radioimmunoassay (RIA) kit and baseline blood glucose levels determined. The 
animals were then injected intraperitoneally with a 50% sucrose solution, to give a final 
concentration 1 mg/kg. Blood glucose levels were monitored over a period of 120 
minutes using a glucometer; blood was collected via a tail prick. At week 14, all the 
animals were anaesthetized with a 160 mg/kg overdose of a sodium pentobarbital 
intraperitoneal (IP) injection. When all sensation was absent, as indicated by no 
response on a foot pinch, the animals were sacrificed via exsanguination. Body weight 
was determined and IP fat dissected out and weighed. Blood samples were collected for 
























Figure 14: The time frame of the type 1 diabetic model 
 
2.3.2. Diet-induced obese insulin resistant rat model 
In this model a total of 56 animals were used and the experiment was conducted for a 
period of 16 weeks. Animals weighing between 180 and 200 g were divided into two 
groups: a control (n=28) and diabetic (n=28) group. The food and water intake of the 
animals were monitored on a daily basis. Animals were put on a high caloric diet 
containing normal rat chow supplemented with sucrose and condensed milk for a period 
of 16 weeks. Treatment with Buchu water commenced either at the onset of the change 
in diet or from week 8 after onset. A group of animals were treated with metformin as a 
positive control. Animals in this model were divided according to Figure 15. 
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-  Buchu water given from day 1 
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Buchu(1)         : Buchu treatment from day 1 
Buchu (8)        : Buchu treatment from 8 weeks 
Metformin     :  Metformin treatment from 8 weeks 
 
Figure 15: Schematic representation of the division of type 2 diabetic animals 
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Metformin treatment was given at a dose of 250 mg/kg/day by oral gavage. At week 15, 
IPGTTs’ (procedure described above) were performed on all animals to test whole-body 
insulin sensitivity. A milliliter of fasting blood was collected for insulin determination. 
After recuperating for one week (week 16), animals were sacrificed via a 160 mg/kg 
sodium pentobarbital IP injection. Body weight and IP fat were measured and, blood 
samples were collected for biochemical analysis. Both soleus muscles were removed 
for determination of insulin sensitivity. The pancreas was removed and stored in liquid 
nitrogen for further biochemical analysis. 
2.4. Western blot analysis 
2.4.1. Sample preparation 
Total proteins are extracted from pancreatic tissue of diet induced obese insulin 
resistant animals followed by Western blot analysis used to investigate the expression 
of certain proteins of interest. The extraction of proteins was made possible by means of 
a lysis buffer which consisted of a wide variety of reagents which inhibited 
phosphatases and enzymes involved in proteolysis. Table 4 summarizes the list of the 





Stellenbosch University  https://scholar.sun.ac.za
62 
 
Table 4: List of reagents for the lysis buffer 
Stock reagents Content Function 
200 mM Tris-HCL  20 mM Buffer with a pH of 7.5 
10  mM EGTA 1 mM A chelating agent that acts as a 
metallo-protease inhibitor 
100 mM EDTA 1 mM Metallo-protease inhibitor 
1M NaCI 150  mM Maintain ionic strength of 
medium 
1 mM β-glycerophosphate 1 mM Non-specific phosphatase 
inhibitor 
2.5 mM tetrasodiumpyrophosphate 2.5 mM Non-specific phosphatase 
inhibitor 
100 mM sodium orthovanadate 1 mM An inhibitor of protein tyrosine 
phosphatases, alkaline 
phosphatases and various 
ATPases 
100% Triton-X100 1% Non-ionic detergent for 
solubilizing membrane proteins 
10 μg/ml Leupeptin 10 μg/ml Protease inhibitor 
10 μg/ml Aprotinin 10 μg/ml Serine protease inhibitor 
100 mM phenylmethyl sulfonyl fluoride 50 μg/ml Irreversible serine protease 
inhibitor 
A Polytron PT10 homogenizer was used to homogenize  tissue in 0.9 ml of ice cold lysis 
buffer. These samples were homogenized twice for 5 seconds on setting 4. The 
homogenized samples were placed on ice for 15 minutes, allowing the buffer to fully 
compromise cellular integrity. Once the samples have settled, the homogenates were 
transferred to specifically marked eppendorf tubes and centrifuged (14 000 rpm for 10 
minutes), at 4°C. After centrifugation, the pellet was discarded and the supernatant 
transferred to a new eppendorf tube.   
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2.4.2. Bradford protein determination assay 
Aliquots of the supernatant were used to determine protein concentrations of each 
sample, using the Bradford assay (Bradford, 1976). Tubes were arranged in a rack 








Figure 16: Tube arrangement for the Bradford protein assay 
 
The supernatant obtained as described in section 2.4.1. was pipetted into tubes within 
line up A. A 1:10 dilution of the supernatant was made by the addition of dH2O to dilute 
the detergent which would otherwise interfere with the assay. In line up B 5 μl of each 
diluted sample was pipetted accordingly, with the addition of 95 μl of H2O. The blank 
tube contained 100 μl of H2O. Diluted bovine serum albumin (BSA) of a known 
concentration, containing protein concentrations of 1-20 µg, were aliquoted into protein 
       Blank       Standards 
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determination tubes. The volume pipetted into each was (μl): 10, 20, 40, 60 and 80, 
followed by the addition of dH2O, making a final volume of 100 μl. A 1:5 dilution of 
Bradford reagent (900 μl) was added to the blank, standards and tubes in line up B. 
Samples were left for 15 minutes to allow proper colour development then read 
spectrophotometrically at an absorbance wavelength of 595 nm. The protein content in 
each sample was calculated from the standard curve established by BSA. Samples 
were diluted with lysis buffer to render equal protein concentrations, and then diluted 













Figure 17: Standard curve generated from the optical density readings 
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2.4.3. Protein separation by gel electrophoresis 
Stored aliquots were boiled for 5 minutes, then microfuged for 2 minutes at 15 000 rpm 
to remove particulate matter. The polyacrylamide gel was prepared and samples were 
loaded (Table 5 shows the proteins used, their concentrations and percentage 
polyacrylamide gel utilized). A protein ladder was included to serve as a marker to 
identify the molecular weight of a particular protein.  These gels were then exposed to 
electrophoresis (SDS-PAGE) in running buffer containing 50 mM Tris, 384 mM glycine 
and 1% SDS, ensuring proper protein separation. A BioRad Mini Protean III system was 
utilized. Proteins were separated using two different settings: 1st run at 100 V, 200 mA 
for 10 minutes and 2nd run at 200 V, 200 mA for 50 minutes.  
 
2.4.4. Transfer of proteins to a membrane 
Running buffer was discarded and proteins were transferred to a polyvinylidene fluoride 
(PVDF) membrane (ImmobilonTM P, Millipore). The transfer of proteins to the PVDF 
membrane was accomplished in transfer buffer (25 mM Tris, 192 mM glycine and 20% 
methanol) at an electrical current of 200V for 1 hour. At the end of the transfer period, 
the membrane was soaked in methanol for 30 seconds and allowed to air dry. 
Membranes were stained with Ponçeau Red reversible stain to visualize the transfer of 
proteins as well as equal loading.    
 
2.4.5. Blocking non-specific sites with milk 
Ponçeau Red was then rinsed off with TBS-tween (Tris-buffered saline containing 0.1% 
Tween-20) repeatedly followed by the membranes being blocked, non-specifically, with 
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5% TBS-tween fat-free milk (5% fat-free milk in Tris-buffered saline- 0.1% Tween 20) for 
2 hours at room temperature. After the blocking period, membranes were rinsed with 
TBS-tween and then probed with primary antibodies directed against specific proteins 
(Table 5) overnight at 4°C.   
2.4.6. Immunodetection of proteins  
After being incubated overnight at 4°C, the membranes were washed with TBS-tween to 
remove any unbound primary antibody and incubated with secondary antibody (anti-
rabbit immunoglobulin G, Horseradish-peroxidase conjugated secondary antibody) for 
one hour at room temperature. This enables the secondary antibody to bind to the 
already bound primary antibody. At the end of the incubation period, membranes were 
rinsed with TBS-tween and then covered with an enhanced chemiluminescence (ECL) 
detection reagent for 1 minute. The horseradish-peroxidase coupled to the secondary 
antibody in conjunction with the ECL chemiluminescent agent facilitates protein 
visualization by producing luminescence in proportion to the amount of protein present. 
Light emission was captured on radiography film and analyzed by laser scanning 
densitometry and suitable software (Silk Scientific Inc, USA).  
In all instances, the mean of the total pixels of the bands generated by controls on a 
specific blot was set as 1 and used to normalize data as a ratio to controls.   
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Table 5: Western blot analysis 
 
 
2.5. 2-Deoxy-D-3[H] glucose (2DG) uptake by soleus muscle 
The soleus muscles were rapidly isolated and sliced into five thin longitudinal strips. 
Each strip was placed into a specific flat-bottomed incubation tube containing incubation 
medium and various other reagents (Table 6). The tubes were gassed with 5% carbon 
dioxide and 95% oxygen. The incubation medium consisted of: 6 mM KCl, 1 mM 
Na2HPO4, 0.2 mM NaH2PO4, 1.4 mM MgSO4, 128 mM NaCl, 10 mM HEPES, 1.25 mM 
CaCl2, 1 mM D-glucose, 2 mM pyruvate and 1% fatty acid free BSA (pH 7.4). The 
incubation tubes were placed in a shaking waterbath at a temperature of 37°C for 15 
minutes. After 15 minutes, insulin was added from a 10 μM stock solution to specific 
tubes to render 1 nM, 10 nM and 100 nM insulin, and incubated for a further 30 minutes 
in the waterbath. Soleus muscle strips were incubated with 1.5 μCi/ml [3H]2DG, in a 
final concentration of 1.8 μM deoxyglucose, for an additional 30 minutes. To stop the 
glucose uptake reaction, phloretin from a stock solution (final concentration of 400 μM) 
was added to all tubes which were then removed from the waterbath. Phloretin is a 
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strips were washed 5 times with incubation medium, transferred to eppendorf tubes 
filled with 500 μl of 1M NaOH. The muscle was fully dissolved in the NaOH solution 
when placed into a 70°C waterbath for 1 hour. Finally, 500 μl of distilled water was 
added to each sample, resulting in a final NaOH concentration of 0.5 M. At this stage 
radioactivity within the tissue as well as the protein content could be determined. An 
aliquot of the homogeneous solution (200 μl) of each sample was mixed with 2 ml of 
scintillation fluid in counting vials which were stored overnight in the dark before being 
counted by a beta-scintillation counter. 
 
The protein content of each sample was determined by the Lowry method [Lowry et al., 
1951] using a standard curve of known BSA concentrations and a 0.5 M NaOH blank. 
The protein assay was performed in duplicate with each tube containing 50 μl of a 
blank, standard or sample. Once the blank, standards and samples were loaded; 1 ml of 
reaction buffer was pipetted into each tube which was then vortexed, and allowed to 
react for 10 minutes at room temperature. The reaction buffer consisted of a 2% 
Na2CO3, 1% CuSO4.5H2O and 2% NaK-tartrate mixture. After 10 minutes, 100 μl Folin 
Ceiocalteus reagent (Merck) (1:2 dilution with distilled water) was added, vortexed and 
left to stand for 30 minutes for full colour development. Absorbance was read at 750 nm 
against the blank. At the end of the assay a standard curve was drawn and unknown 
concentrations were determined. 
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(μl)   
(Tube 2) 
1nM Insulin 
(μl)         
(Tube 3) 
10nM Insulin 
(μl)          
(Tube 4) 
100nM Insulin 




Strip Strip Strip Strip Strip 
Incubation 
medium 
675 675 600 600 600 
Phloretin 0 50 0 0 0 
Insulin 0 0 75 75 75 
2-deoxy-D-
[3H] glucose 
25 25 25 25 25 
Phloretin 
(block) 
50 0 50 50 50 
Total (μl) 750 750 750 750 750 
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2.6. Biochemical analysis 
 
2.6.1. Blood sample collection 
 
Blood samples were allowed to stand on ice for 30 - 60 minutes to permit clotting. 
Samples were then subjected to centrifugation for 10 minutes at 14 000 rpm at 4°C. The 
serum was then pipetted into eppendorf tubes and stored at -80°C for further 
biochemical analysis. 
 
2.6.2. Serum insulin determination 
 
The Coat-A-Count Insulin assay (Count-A-Count®Insulin Diagnostics Corporation; LA, 
USA) is a solid phase 125I radioimmunoassay designed to quantitatively measure insulin 
in serum. In this assay 125I-labeled insulin and insulin in the serum samples compete for 
sites on insulin-specific antibodies. These antibodies are immobilized to the wall of 
polypropylene tubes and competition can be terminated by simply decanting the 
supernatant. This step isolates the antibody bound fraction of radio-labelled insulin.  
 
Components of the entire procedure were brought to room temperature (15-28°C), prior 
to the onset of the assay. All samples were analyzed in duplicate. Plain uncoated 
polypropylene tubes (12 x 75 mm) were labeled for total counts (T) and non-specific 
binding (NSB), respectively. Fourteen insulin-antibody coated tubes were labeled for 
standards and additional tubes were labeled for samples. The addition of insulin 
calibrators and iodinated insulin (125I insulin) are depicted below. 
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    Duplicate 
Table 7: A representation of calibrators  
 
 



























     Figure 18: Diagrammatic layout of tube labelling and preparation  
    Plain uncoated tubes 
    Coated tubes 
       A        B        C        D        E        F        G 
       T        T        N        NSB      NSB
      200 μl calibrator A 
      200 μl calibrator B 
      200 μl calibrator C 
      200 μl calibrator D 
      200 μl calibrator E 
      200 μl calibrator F 
      200 μl calibrator G 
      1ml 125I insulin 
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  200 μl of standards or samples in duplicate, were pipetted into the bottom of the 
reaction tubes. Here after, the radio-labelled insulin was added, and the tubes were 
incubated for 18-24 hours at room temperature. After the elapsed time, samples were 
decanted thoroughly using a decanting rack, then struck repeatedly on absorbent paper 
to remove excess residue. Tubes were carefully dried to remove all traces of unbound 
radioactive material.  Radioactivity of each tube was counted for 1 minute in a gamma 
counter. The standard curve (Figure 18: an example of a standard curve) formed a 













Figure 19: Standard curve generated by the gamma counter 
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 2.6.3. Enzyme Linked Immunosorbent Assay (ELISA) 
       Previously stored serum was utilized to determine C-peptide levels of each sample 
using an Elisa kit (Abcam Ltd, Cambridge, UK). In this assay, C-peptide molecules in 
the sample bind to the wells of a microtiter plate, coated with a pre-titered amount of 
anchor antibodies. Binding of a second biotinylated antibody to insulin occur 
simultaneously. The microtiter plate consists of 96 wells which were divided into blanks, 
standards, quality control (QC) and samples as seen in Table 8. 
       Table 8: Microtiter plate arrangement 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Blank 200 pM QC1 Etc.         
B Blank 200 pM QC1 Etc.         
C 25 pM 400 pM QC2          
D 25 pM 400 pM QC2          
E 50 pM 800 pM Sample 1          
F 50 pM 800 pM Sample 1          
G 100 pM 1,600 pM Sample 2          
H 100 pM 1,600 pM Sample 2          
  This assay was done in duplicate 
       Washing procedure:  Wells were washed three times with 300 μl of diluted (1x) wash 
buffer and then decanted. The remaining wash buffer was removed by inverting the 
plate and tapping it on absorbent towels several times. 
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       Matrix solution (20 μl) was added to blank, standard and quality control wells. Followed 
by 30 μl of assay buffer to blank and sample wells. Standard and QC wells were filled 
with 10 μl of assay buffer. Rat insulin standards (20 μl) were added to specific wells in 
ascending order while 20 μl of QC1 and 20 μl of QC2 were added to wells labeled QC. 
The remaining wells were filled with 20 μl of the unknown sample. 50 μl of the antibody 
solution mixture (a mixture which consists of capture and detection antibody at a 1:1 
ratio) were added to each well. The plate was then covered with a plate sealer and 
incubated for 2 hours at room temperature on an orbital microtiter plate shaker (400-500 
rpm). After 2 hours, the plate sealer was removed and the solution decanted from the 
plate. Residual solution was removed using a tapping motion and wells were washed 
according to the washing procedure. Enzyme solution (100 μl) was added to each well, 
the plate covered and incubated on the shaker at room temperature for 30 minutes. 
Once the time has elapsed, the sealer was removed, the solution decanted and the 
wells washed according to the washing procedure. Substrate solution (100 μl) was 
added to each well, the plate sealed and placed on a shaker for approximately 20 
minutes. In standard wells, a blue pigment was observed with intensities proportional to 
increases in insulin concentrations. Stop solution (100 μl) was added to each well, and 
then shaken by hand to ensure complete mixing of the solution.  At this stage, the blue 
pigment turned into a yellow colour. The intensity of the yellow colour was read at an 
absorbance value of 450 nm and 590 nm in a plate reader and the two readings 
subtracted from each other. The standard curve (Figure 20: an example of a standard 
curve) obtained was used to quantitatively determine the concentration of C-peptides in 
experimental serum samples.   



















Figure 20: A graph of a typical standard curve 
 
2.7. Statistical Analysis  
Statistical analysis of data was performed using GraphPad Prism 5. All values are 
expressed as the mean ± standard error of the mean (SEM). For multiple comparisons, 
the ANOVA (two-way when appropriate) followed by the Bonferroni post-hoc test was 
applied. A p-value of less than 0.05 (p<0.05) was considered as statistically significant. 






3.1. Type 1 Diabetes 
The T1D model (STZ) was induced by using streptozotocin, a glucose moiety which is 
easily transported into pancreatic β-cells via GLUT 2 carrier proteins [Wei et al., 2003; 
Motyl and McCabe, 2009]. Streptozotocin exerts its toxic effects by damaging DNA, 
eventually, leading to β-cell dysfunction, hypoinsulinemia and hyperglycemia; all 
characteristics associated with diabetes [Motyl and McCabe, 2009].  Refer back to 
Figure 14 for an illustration of the experimental procedure.  
3.1.1. Biometric parameters 
3.1.1.1. Food and water/Buchu consumption  
On the first day of STZ administration; control and STZ animals were divided into their 
respective groups and treated with Buchu water at the start of the experiment (day 1) 
and three weeks after the initiation of the experiment (Buchu week 3). Each group 
contained 10 animals, 5 per cage. Animals that spontaneously normalized were 
excluded from the study. Food and water/Buchu water consumption were monitored for 
a period of 1 week and 20 days, respectively, 3 weeks after the start of the experiment. 
When comparing each cage, no significance was observed between any of the groups 
when inspecting food and water/Buchu water consumption (Figure 21 and Figure 22). 
However, a decrease in food consumption in STZ and control treated animals were 
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observed. This could be as a result of Buchu water having effects on the satiety centre 
thus reducing appetite. The bitter taste of Buchu water could have contributed to the 



































































Figure 21: Food consumed by control and STZ animals, from week 3.  Displayed is 
food consumption measured in grams (g) of streptozotocin (STZ) and control animals. 
The data is presented as a mean ± SEM. (n=10/group) 














































































Figure 22: Water/Buchu water consumed by control and STZ animals, from week 
3. Displayed is water/Buchu water consumption measured in millilitres (ml) of 
streptozotocin (STZ) and control animals. The data is presented as a mean ± SEM. 
(n=10/group) 
 
3.1.1.2. Body weight and intra-peritoneal fat mass 
After 14 weeks of feeding, animals were anaesthetized and sacrificed. At this time point, 
their body weight and intra-peritoneal fat mass was determined. Measurements of each 
animal in their respective groups were recorded and plotted diagrammatically. When 
comparing each group, significantly lower body weight was observed in the STZ treated 
vs control animals (284.3 ± 9.9 vs 345.4 ± 7.6 g; p<0.0001) (Figure 23). This lower 
weight was exacerbated by Buchu water ingestion in the STZ animals (284.3 ± 9.9 vs 
242.4 ± 10.9 g (day 1; p<0.05) and 240.3 ± 9.0g (week 3; p<0.05) respectively. 
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Similarly, control animals treated with Buchu water gained less weight than untreated 











































































Figure 23: Body weight (BW) of control and STZ animals, with and without Buchu 
treatment, after 14 weeks. Displayed is body weight measured in grams (g) of 
streptozotocin (STZ) and control animals. The data is presented as a mean ± SEM. 
(n=10/group). *p<0.05, ***p<0.0001 
       
A difference in body weight was observed. However, STZ animals treated with Buchu 
presented with significantly more intra-peritoneal fat than the untreated animals 
(14.79±2.5g (day 1), 13.41±1.6g (week 3) vs 9.66±0.7g respectively. 
 






















































































Figure 24: Intra-peritoneal (IP) fat of control and STZ animals, with and without 
Buchu treatment, after 14 weeks. Displayed is IP fat mass measured in grams (g) of 
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 3.1.2. Metabolic parameters 
3.1.2.1. Blood Glucose Levels 
On day 1, animals were divided into 4 groups containing 5 animals per cage. 
Respective animals were treated with STZ from day 1 and Buchu from week 3. Non-
fasting blood glucose levels of all animals were determined weekly for 12 weeks, 
starting at week 3. A drop of blood from a tail prick was collected. After 14 weeks, blood 
glucose levels of STZ animals treated with Buchu were significantly lower than 
untreated STZ animals. A significant decline was also seen in STZ animals with blood 
glucose levels more than 20 mmol/L at the start of experimentation (Figure 25 (B) and 
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*p<0.05         
**p<0.01 
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Figure 25: Weekly blood glucose levels of control and STZ animals, with and 
without Buchu treatment, for 12 weeks. (A) Representation of all groups, (B) 
Comparing treated streptozotocin animals with blood glucose levels at the onset of 
experimentation greater than (>20) and less than 20 mmol/L (<20), (C) Comparing 
treated streptozotocin animals (blood glucose levels < 20 mmol/L) with untreated 
streptozotocin animals, (D) Comparing untreated streptozotocin animals with treated 
streptozotocin animals (blood glucose levels > 20 mmol/L), and (E) Comparing 
untreated control and streptozotocin animals. Blood glucose levels were measured in a 
non-fasting state and expressed in mmol/L. The data is presented as a mean ± SEM. 
(n= 5/group). 
       *** 
       ***        *** 
       *** 
       ***        ***        *** 
       *** 
       *** 
       ** 
       ** 
**p<0.01         
***p<0.001 
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3.1.2.2. Intraperitoneal glucose tolerance test (IPGTT) 
At 13 weeks, all animals following their respective treatment regimes, were fasted 
overnight. The next day, intraperitoneal glucose tolerance tests were performed on each 
animal for a period of 2 hours. When comparing treated and untreated controls, no 
significant difference was seen (Figure 26 (F)). However, a significant decrease 
(***p<0.001) in blood glucose levels were observed when comparing treated and 
untreated streptozotocin animals (Figure 26 (B) and (C)). At the 2 hour mark, averages 
of each group were calculated and plotted using a bar graph (Figure 26 (G)). From this 
graph it is clear that the consumption of Buchu water resulted in an improved ability to 


























STZ, Buchu week 3 (24hr: <20)
STZ, Buchu week 3 (24hr: >20)
Control, untreated
























































       *** 
       ***        ***        ***        ***        ***        ***        *** 
       *** 
       *** 
       *** 
***p<0.001 






































































       *** 
       *** 
       *** 
       *** 
       *** 
       *** 
       *** 
       *** 
       *** 
       *** 
       *** 
***p<0.001 
       *** 
       *** 
       *** 
      *** 
       *** 
       *** 
       *** 
      *** 
       *** 
       *** 
       *** 










STZ, Buchu week 3
 (24hr: <20)



































































































































Figure 26: Intraperitoneal glucose tolerance test of control and STZ animals, with 
and without Buchu treatment, at 13 weeks. (A) Representation of all groups, (B) 
Comparing treated streptozotocin animals (blood glucose levels < 20 mmol/L) with 
untreated streptozotocin animals, (C) Comparing treated streptozotocin animals (blood 
glucose levels > 20 mmol/L) with untreated streptozotocin animals, (D) Comparing 
untreated streptozotocin and control animals, (E) Comparing treated streptozotocin 
animals with blood glucose levels greater than 20 mmol/L and less than 20 mmol/L, (F) 
Comparing treated and untreated control groups, and (G) IPGTT 2 hour values of 
control and streptozotocin groups. Blood glucose levels were measured in mmol/L. The 
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3.1.2.3. Serum Insulin levels 
Following 14 weeks on diet, no significant difference in fasting serum insulin levels were 
observed when treated and untreated STZ animals were compared, as well as between 
treated and untreated control animals (Figure 27). 
 
 
Figure 27: Fasting serum insulin levels in control and STZ animals, with and 
without Buchu treatment, after 14 weeks. Displayed, are fasting serum insulin levels 
of treated and untreated streptozotocin (STZ) and control animals. The data is 
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3.2. Type 2 Diabetes 
The T2D model (DIO) was generated by feeding animals with a high caloric diet 
containing normal rat chow supplemented with sucrose and condensed milk for a period 
of 16 weeks. This diet correlates with changes seen in humans, changing from a rural to 
a more westernised diet. The diet induced obesity and insulin resistance.  Below is a 
table (Table 9) indicating the macronutrient composition of diets consumed by control 
and DIO animals. 
Table 9: Diet composition of controls versus DIO animals [Du Toit et al., 2008; 
Pickavance et al., 1999] 
 
 Control DIO 
Carbohydrates 60% 65% 
Protein 30% 19% 
Fat  10%  16% 
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3.2.1. Biometric parameters 
3.2.1.1. Food and water/Buchu consumption 
On day 1, control and DIO animals were divided up into their respective groups, treated 
with Buchu at various time points. Each group contained 8 animals, 4 per cage. Food 
consumption was monitored for a period of 1 week while water/Buchu consumption was 
monitored daily for 10 days, both readings were recorded from week 8. There were no 
difference in the amount of food consumed (Figure 28). Furthermore, no significance 
was observed between any of the groups when inspecting water/Buchu water 




























































































Figure 28: Food consumed by control and DIO animals, from week 8.  Displayed is 
food consumption measured in grams (g) of diet induced obese (DIO) and control 
animals. The data is presented as a mean ± SEM. (n=8/group).  






































































































Figure 29: Water/Buchu water consumed by control and DIO animals, from week 
8. Displayed is water/Buchu consumption measured in millilitres (ml) of diet induced 
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3.2.1.2. Body weight and intra-peritoneal fat mass 
After 16 weeks of feeding, animals were anaesthetized and sacrificed. Their body 
weight and intra-peritoneal fat mass were weighed. The DIO animals gained 
significantly more weight than their control counterparts (507.4±12.3 vs 403.6±20.1g, 
p<0.0001, n=5). When comparing each group, a significant difference in body weight 
was also observed between untreated and treated DIO animals (507.4±12.3 vs 
460.4±8.4 (day 1) and 455±9.7g (wk8) p<0.05, n=5/group. Metformin treatment also 
resulted in significant less weight gain vs the untreated DIO animals (415.8±14.9 vs 

















































































Figure 30: Body weight (BW) of control and DIO animals, with and without Buchu 
treatment,  after 16 weeks. Displayed is body weight measured in grams (g) of diet 
induced obese (DIO) and control animals. The data is presented as a mean ± SEM. 
(n=5/group). *p<0.05, ****p<0.0001. 
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The DIO animals presented with significantly more intra-peritoneal fat mass than all the 
control groups (Figure 31). DIO=24.24±3.8g vs control=10.6±0.9g, control with Buchu 
from day 1 = 10.4±0.5g and control with Buchu from wk 8 = 9.3±0.5g, p<0.001, 
n=5/group.  In addition, metformin resulted in significantly less intra-peritoneal fat mass 



















































































Figure 31: Intra-peritoneal (IP) fat of control and DIO animals, with and without 
Buchu treatment, after 16 weeks. Displayed is IP fat mass measured in grams (g) of 
diet induced obese (DIO) and control animals. The data is presented as a mean ± SEM. 
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3.2.2. Metabolic parameters 
3.2.2.1. Intraperitoneal glucose tolerance test (IPGTT) 
At 15 weeks, all animals following their respective treatment regimens were fasted 
overnight. The next day, intraperitoneal glucose tolerance tests were performed on each 
animal for a period of 2 hours. When comparing treated and untreated controls, no 
significant differences were seen (Figure 32 (B)). However, a significant difference in 
blood glucose levels were observed when comparing treated and untreated DIO 
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Figure 32: Intraperitoneal glucose tolerance test of control and DIO animals, with 
and without Buchu treatment, at 15 weeks. (A) Representation of all groups, (B) 
Comparing all control groups, (C) Comparing untreated DIO and control groups, (D) 
Comparing untreated DIO animals with treated DIO animals (buchu water from day 1), 
(E) Comparing untreated DIO animals with treated DIO animals (buchu water from week 
8), (F) comparing DIO animals treated with Buchu water from day 1 and week 8. Blood 
glucose levels were measured in mmol/L. The data is presented as a mean ± SEM. (n: 
2-10/group) 
 
3.2.2.2. 2-Deoxy-D-3[H] glucose (2DG) uptake by soleus muscle 
At 16 weeks, 4 animals per group were anaesthetized, the soleus muscles were rapidly 
isolated and sliced into five thin longitudinal strips. Each strip was placed into a specific 
flat-bottomed incubation tube containing incubation medium and various other reagents 
(Table 6). The purpose of this procedure was to determine muscle sensitivity to insulin. 
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Neither basal glucose uptake levels nor insulin sensitivity differed in these muscles 





























Figure 33: Glucose uptake by the soleus muscle of control and DIO animals, with 
and without Buchu treatment, after 16 weeks. Insulin sensitivity of the soleus muscle 
was determined by measuring the ability of the muscle to accumulate radio-labelled 
deoxy-glucose over a set time period. The data is presented as a mean ± SEM. (n= 
4/group) 
 
3.2.2.3. Serum insulin levels 
Following 16 weeks on diet, serum insulin levels were not significantly different between 
the control and DIO animals without Buchu treatment (22.58±5.8 vs 20.99±2). However, 
starting Buchu water treatment at the onset of the change in diet, resulted in lower 
insulin levels (DIO: 20.99±2 vs 11.12±2; Control: 22.58±5.8 vs 9.95±0.9). 
   Insulin 
Stellenbosch University  https://scholar.sun.ac.za
100 
 
Starting the Buchu water treatment on week 8 after onset of the obesity-inducing diet, 
could not lower insulin levels in the DIO animals. To the contrary, insulin levels were 
raised significantly (22.58±5.8 vs 37.5±2.7) (Figure 34A). Figure 34B depicts a 2-way 
ANOVA analysis of the effect of Buchu water on insulin levels in both control and DIO 
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Figure 34: Fasting insulin levels in control and DIO animals after 16 weeks.  
Fasting blood was drawn under anaesthesia directly from the carotid artery and insulin 
levels determined using a RIA assay as described in Materials and Methods. The data 
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3.2.2.4. C-peptide levels  
C-peptide levels of blood collected from the animals treated with Buchu water from  
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Figure 35: C-peptide levels in control and DIO animals after 16 weeks. A significant 
difference was found in C-peptide levels of treated vs untreated DIO animals. The data 
is presented as a mean ± SEM.  (n=4-6/group).  
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3.2.2.5 Pancreatic Transcription Factors 
Following 16 weeks on their respective diets, animals were anaesthetized and 
pancreatic tissue isolated and stored at -80°C. These tissues were used to determine 
the effect of Buchu treatment on the expression of Pdx-1 and MafA in DIO and control 
animals. Ponceau staining was used as a loading control. 
3.2.2.5.1. Pdx-1 
Pdx-1 expression was downregulated in DIO pancreata compared to controls. A 
significance increase in Pdx-1 expression was observed when comparing treated and 
untreated DIO animals, while the total effect of Buchu treatment as indicated by a 2-way 
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Figure 36: Total Pdx-1 expression in control and DIO groups after 16 weeks. 
Shown is an example of a western blot representing Pdx-1 expression as well as a 
graph depicting protein expression in arbitrary units. The data is presented as mean ± 
SEM. The data is presented as a mean ± SEM. (n = 4/group) *p<0.05  
 
3.2.2.5.2. MafA 
MafA expression was downregulated in DIO pancreata compared to controls. A 
significant increase in MafA expression was observed when comparing treated and 
untreated DIO animals. A 2-way ANOVA indicated a significant effect of Buchu water 
treatment on the expression of MafA (Figure 37).  
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Figure 37: Total MafA expression in control and DIO groups after 16 weeks. 
Shown is an example of a western blot representing MafA expression as well as a 
graph depicting protein expression in arbitrary units. The data is presented as mean ± 
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It has been estimated that 347 million people worldwide have diabetes mellitus, with 
approximately 80% of diabetic deaths occurring in low and middle income countries 
[Mathers and Loncar, 2006; WHO, 2014]. Diabetes mellitus is a chronic disease 
associated with disastrous complications, wreaking havoc amongst individuals of all 
ages. According to the World Health Organisation (WHO), diabetes will be the 7th 
leading cause of death by the year 2030. As a result, much research has been 
conducted on the pathophysiology of diabetes mellitus as well as the establishment of 
safer, more convenient treatment options. 
The people of South Africa are faced with many challenges on a daily basis, especially 
where healthcare is concerned. In developing countries, treating chronic diseases are 
either too expensive or inaccessible. South Africa is a country rich in floral biodiversity, 
shifting attention toward the medicinal use of indigenous plants [Light et al., 2005].  
There are many complex issues surrounding the use of indigenous plants in medicine. 
One of these issues stem from the fact that the use of medicinal plants were based on 
hearsay [Light et al., 2005]. 
The indigenous plant of interest for this study belongs to the genus Agathosma and is 
collectively known as Buchu.  It is claimed that Buchu exert various beneficial effects 
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which still need to be scientifically validated. A study reviewed by Moolla and Viljoen 
successfully validated that Buchu exerts anti-microbial, anti-inflammatory, anti-oxidant 
and diuretic effects [Moolla and Viljoen, 2008]. Whether buchu has any anti-diabetic 
properties, remains a question which demands scientific investigation.  
The aim of our study was therefore to investigate the anecdotal claims of anti-diabetic 
effects experienced by individuals using Buchu water. Buchu water is the by-product of 
the extraction of Buchu oil. The latter is mainly isolated from the leaves of Agathosma 
crenulata and Agathosma betulina, both endemic to the mountains of the Western Cape 
in South Africa. The oil is used as a flavour enhancer in the perfume and food 
industries. The aqueous solution is currently marketed as a herbal remedy to treat 
various ailments e.g., urinary infections, rheumatism, arthritis and obesity. People 
ingesting the water started claiming insulin sensitizing potential necessitating scientific 
validation of these claims.  
Moolla and Viljoen (2008) comprehensively reviewed the phytochemical composition of 
Buchu oil.  In Buchu oil, there is only one family of substances that may be harmful – 
the pulegones.  However, during fractionation, the pulegones are extracted in the oil 
fraction with less than 0.1% present in the water fraction. In addition to pulegone Buchu 
oil consists of limonene, menthone and diosphenol. Currently, little is known about the 
composition of Buchu water as well as the active substance present.  
 
 




One of the main findings of this study is that ingestion of Buchu water results in weight 
loss despite unchanged food consumption.  This occurred in both the models used as 
well as control animals.  In the obese animals, this weight loss was due to the loss of 
intra-peritoneal fat.   
A second important finding is that the ingestion of Buchu water in all instances, whether 
given as treatment or as prophylactic, resulted in normalization of glucose levels in a 
type-1 diabetic model with residual beta-cell mass.  
An insulin-sensitizing effect has not been clearly established in the muscle of DIO 
animals but this may be because of a large variation in values obtained as well as the 
use of a slow-twitch muscle.  
A definite effect on pancreatic insulin secretion has been demonstrated by raised C-
peptide levels in DIO treated animals. 
4. Diabetic models 
4.1. Streptozotocin-induced type 1 diabetic model 
Type 1 Diabetes is an organ specific autoimmune disease caused by the immunological 
destruction of insulin producing pancreatic β-cells [Narendran et al., 2003; Atkinson and 
Eisenbarth, 2001]. The destruction of β-cells minimizes β-cell mass, thus, exposing the 
body to hyperglycemia. High blood glucose levels are associated with a vast array of 
detrimental effects such as glucotoxicity and ketoacidosis. 
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Streptozotocin is a glucosamine compound, derived from a soil microbe called 
Streptomyces achromogenes, which is easily transported into pancreatic β-cells via 
glucose transporter 2, where it exerts its toxic effects by damaging DNA [Wei et al., 
2003; Motyl and McCabe, 2009; Arora et al., 2009]. This leads to β-cell dysfunction, 
hypoinsulinemia and hyperglycemia; all characteristics associated with diabetes [Motyl 
and McCabe, 2009]. The severity of type 1 diabetes depends on the species of the 
animal, age and amount of STZ administrated intravenously or intraperitoneally [Arora 
et al., 2009].  In this study, we successfully developed a type 1 diabetic model by 
injecting rats with a single dose of STZ (40 mg/kg), intra-peritoneally. In these animals, 
approximately 50 % of the total pancreatic β-cell mass was ablated [George et al., 2011] 
leading to blood glucose levels within the range of >10<20 mmol/L. Diabetic animals 
were further divided into a group with blood sugar values less than 20mmol/L and those 
with values exceeding 20mmol/L.  This was clearly seen when weekly evaluating blood 
glucose levels of STZ animals after 11 weeks treatment (Figure 25). Additionally, fasting 
blood glucose levels of untreated STZ animals at week 13 were significantly higher  
compared to treated STZ animals (Figure 25 and Figure 26).  
The streptozotocin-induced type 1 diabetic model was further used to determine the 
effect of Buchu water on certain biometric and metabolic parameters. 
4.1.1. The effect of Buchu water on biometric parameters  
In the current study, water/Buchu water and food consumption were monitored to 
determine whether all treated animals consumed equal amounts of Buchu water and 
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whether this consumption might influence their food intake. Daily measurements 
showed no significant differences within or between groups (Figure 21 and Figure 22). 
After 14 weeks of feeding, all animals were anaesthetized with sodium pentobarbital 
and sacrificed. At this point, body weight and intra-peritoneal fat mass were measured. 
The data retrieved was plotted and clear differences in body weight between STZ 
treated and untreated animals were evident (Figure 23). As would be expected, the STZ 
animals gained less weight than their control counterparts but in both STZ animals, as 
well as in the control animals, ingestion of Buchu water resulted in significant lower 
weight gain over the treatment period [Singh et al., 2006]. The lower weight gain seen in 
STZ animals are not good and could result in ketoacidosis. However, when evaluating 
intra-peritoneal fat, the STZ animals ingesting Buchu water, accumulated more fat than 
untreated animals (Figure 24).  In the setting of type 1 diabetes, intra-peritoneal fat 
accumulation but loss of body weight with equal food consumption, might point towards 
either muscle wasting or a higher thermogenic state. It is possible that Buchu water 
might act as a thermogenic supplement by increasing the metabolic rate of cells leading 
to weight loss [Jitomir et al., 2008; Preuss et al.,2002]. This is an aspect of the results 
that needs further investigation.   
4.1.2. The effect of Buchu water on metabolic parameters  
Non-fasting blood glucose levels of all animals were measured and recorded weekly for 
13 weeks. From the data gathered, Buchu treatment resulted in a decrease in blood 
glucose levels over time with the most significant decrease observed in STZ animals 
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that had a lower blood glucose level (< 20 mmol/L) at the onset of experimentation 
(Figure 25).    
At week 13, animals were fasted overnight then anaesthetized in order to perform intra-
peritoneal glucose tolerance tests. All STZ animals that were treated with Buchu water, 
presented with normalized IPGTT curves (Figure 26). This was underscored by a 2hr 
value not significantly different from control animals (Figure 26G). It can therefore be 
concluded that, in this STZ model of type 1 diabetes, treatment with Buchu water 
normalized blood glucose values and served as an effective treatment in the absence of 
any other treatment.  
Despite this normalization of the blood glucose values, we could not detect any 
significant differences in the insulin secretion of these animals (Figure 27).  It is 
therefore possible that the Buchu water treatment may have lowered either the uptake 
of glucose from the intestinal mucosa by the SGLT-1 transporter [Steel and Hediger, 
1998; Srichamroen, 2007] or it may have enhanced glucose excretion by inhibition of 
the SGLT-2 glucose transporters in the kidney [Review: Rosenwasser et al., 2013].  It 
has been shown that inhibitors of SGLT-2 improve glucose control to an extent 
comparable to other hypoglycemic agents while simultaneously reducing body weight. 
[Review: Rosenwasser et al., 2013].   These inhibitors, like canagliflozin or dapagliflozin, 
are of the most recent substances approved for treatment of diabetes. In addition, we 
have noticed that the insulin levels of STZ untreated animals were very high, this could 
have occurred as a result of inadequate insulin breakdown.  
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4.2. Diet-induced obese type 2 diabetic model 
Type 2 Diabetes is a multi-factorial disorder that accounts for 90-95% of all diabetic 
cases worldwide, making it the most common type of diabetes known [Stumvoll et al., 
2005]. T2D occurs as a result of insufficient insulin production by pancreatic β-cells or 
reduced insulin action at target tissues. A strong correlation exists between T2D and 
obesity, while obese individuals undergo metabolic changes which encompass 
dyslipidemia, hypertension, insulin resistance and proinflammation [Chen and Morris, 
2007; Stumbo et al., 2005].   
In our second model we set out to test treatment with Buchu using a type 2 diabetic 
model in which male Wistar rats were fed a high caloric diet for 16 weeks, while control 
animals were fed normal rat chow for the duration of the experiment. The high caloric 
diet consisted of normal rat chow supplemented with condensed milk and sucrose. In 
this respect, DIO animals consumed more energy than control animals per day. Several 
studies have validated that an energy imbalance, where energy intake exceeds energy 
expenditure, is linked to obesity and insulin resistance [Chen and Morris, 2007; 
Pulgarόn, 2013]. Although this diet was sufficient in establishing hyperglycemia, it did 
not result in T2D as the fasting blood glucose values were still below 8 mmol/L.  
4.2.1. The effect of Buchu water on biometric parameters 
 Food consumption was recorded over a period of 7 days with no differences in food 
consumption (Figure 28).  In addition, water/ Buchu water consumption was monitored 
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for the duration of 20 days with no significant differences present within or between 
groups (Figure 29).   
Body weight gain in untreated DIO animals was significantly higher than that of the 
untreated controls (Figure 30) despite similar food intake. This can be ascribed to the 
higher caloric density of the food that they ingested (Table 9).  Additionally, when 
evaluating intra-peritoneal fat, a significant difference was seen when comparing the 
untreated DIO and control groups (Figure 31). It would therefore seem that the DIO 
animals became centrally obese. 
Similar to what was observed in the STZ animals, the ingestion of Buchu water from day 
1 of the change in diet by the DIO animals, resulted in significantly less weight gain, 
similar to the positive control, metformin. Metformin acts by lowering glucose production 
by the liver thereby curbing appetite, resulting in weight loss [Hundal et al., 2000; Lee 
and Morley, 2012]. However, treatment with Buchu water from week 8 of the diet, could 
not induce a significant reduction in weight gain. This effect was also not seen in the 
control animals treated with Buchu water. However, there is a clear trend for lower IP fat 
gain in both the DIO and the control animals ingesting Buchu water.  This effect of lower 
weight gain induced by Buchu water despite equal food consumption, is not clearly 
understood but warrants an investigation of the fat depots of these animals and the 
accompanying adipokines that may affect this, e.g. leptin levels.   
 
 
Stellenbosch University  https://scholar.sun.ac.za
114 
 
4.2.2. Anti-diabetic and insulin sensitizing effects of Buchu water 
4.2.2.1. The effect of Buchu water on insulin secretion and glucose homeostasis 
When pancreatic β-cells are exposed to hyperglycemia they adapt by increasing 
metabolism and ATP production [Layden et al., 2010]. This adaptation causes a surge 
in the ATP/ADP ratio, resulting in the closure of the ATP-sensitive potassium channels 
leading to an influx of calcium. This results in increased insulin release via exocytosis 
[Layden et al., 2010; Li et al., 2007]. Insulin secreted by β-cells is readily available due 
to prior synthesis and storage in immature secretory vesicles containing endoprotease 
and carboxypeptidase E [Robinson, 2013]. Once β-cells are exposed to appropriate 
stimuli, proinsulin is cleaved releasing insulin and C-peptides into circulation [Halban 
and Irminger, 2003]. Insulin is a potent anabolic hormone, responsible for  disposal of 
excess glucose  in response to hyperglycemia [Satiel and Pessin, 2002]. Insulin lowers 
blood glucose levels by stimulating glucose uptake by peripheral tissue and lowering all 
processes involved in glucose production.  
In the current study, IPGTTs done on various groups showed a significantly higher 
fasting blood glucose level in DIO treated animals compared to untreated DIOs , with no 
significant differences between untreated control and DIO animals (Figure 32). When 
monitoring glucose uptake in the soleus muscle under stimulated and basal conditions, 
no significant difference between groups was present (Figure 33). Interestingly, a 
significant increase in serum insulin levels of Buchu treated DIO animals at week 8 was 
observed when comparing this group to its untreated counterpart (Figure 34). However, 
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blood glucose levels were higher in DIO animals, even after treatment and although not 
significant the DIO muscle appears to be insulin resistant (Figure 33). This may account 
for increased insulin values. 
4.2.3. Buchu water as an insulin sensitizing agent/ promoter 
There are many factors capable of reducing insulin sensitivity at peripheral tissues such 
as insulin resistance and defects in insulin signalling. A strong relationship exists 
between insulin resistance and obesity which are associated with a variety of co-
morbidities such as type 2 diabetes [Stumbo et al., 2005; Sahani et al., 2010; Chen and 
Morris, 2007]. In obese individuals energy intake exceeds energy expenditure, leading 
to an accumulation of free fatty acids. In these individuals, adipose tissue can no longer 
effectively clear circulating free fatty acids due to these tissues reaching their optimum 
storage capacity [Goossens, 2008]. Lipids would then accumulate in non-adipose tissue 
but with time they too will lose the ability to oxidize fat effectively [Goossens, 2008]. The 
accumulation of lipids in non-adipose tissue has detrimental effects on insulin sensitivity 
eventually causing insulin resistance within these tissues. For possible mechanisms in 
which free fatty acids causes insulin resistance refer back to section 1.6.2.1 of the 
literature review.  In response to insulin resistance, β-cells would secrete more insulin to 
overcome resistance. This compensatory mechanism usually results in 
hyperinsulinemia, which is accompanied by glucose intolerance, hyperlipidemia and 
hyperglycemia. The manifestation of insulin resistance at insulin’s target tissue usually 
occurs due to an impairment in insulin action. However, analyzing insulin sensitivity of 
soleus muscle did not show clear signs of peripheral insulin resistance in our DIO 
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model, nor did ingestion of Buchu water affect this, although there was a strong trend to 
enhanced insulin stimulated glucose uptake, the variation in data was quite large.   A 
possible effect of the Buchu water on insulin sensitivity is underscored by the significant 
lowering of insulin levels with treatment for the full 16 weeks.  An effect on insulin 
secretion induced by Buchu water treatment was clearly demonstrated by the fact that 
c-peptide levels were significantly raised in DIO treated animals. This effect was further 
investigated by analyzing pancreatic tissue for transcription factors known to be 
associated with enhanced insulin production. 
4.2.4. Buchu water promotes β-cell neogenic activity 
Adult β-cell mass are dynamic components which readily adapt to changes in insulin 
demand or glucose concentrations. To maintain an optimal glucose level, an exquisite 
balance exists between insulin biosynthesis, stimulation and secretion. β-cell mass is 
influenced by an interplay between β-cell growth and loss. For this study, we will only be 
focusing on β-cell growth, specifically, neogenesis. 
 β-cell neogenesis is a mechanism that triggers the generation of new β-cells from 
precursor cells [Paris, 2004]. These precursor cells originate from ductal cells (budding 
from duct epithelium), differentiated pancreatic cells through a process called 
transdifferentiation and intra islet precursors [Paris, 2004]. Under normal conditions, β-
cell neogenesis is at its optimum working capacity prenatally and for a short period of 
time after birth [Masiello, 2006]. As individuals age, neogenesis stabilizes while 
apoptotic activity increases, leading to a reduction in β-cell mass [Masiello, 2006].  
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There are various transcription factors promoting β-cell neogenesis by targeting β-cell 
differentiation, proliferation, and/or pancreatic development [Rocques et al., 2007].  
In our study we determined the effect of Buchu treatment on the expression of 
transcriptional factors involved with β-cell neogenesis, namely, Pdx-1 and MafA. The 
levels of both of these transcription factors were significantly lower in pancreata from 
the DIO animals. This could therefore explain why the DIO model did not present with 
enhanced insulin secretion as would be expected. The overall effect of Buchu treatment 
was significant while increasing Pdx-1 and MafA expression (Figure 36 and Figure 37).  
This observation warrants further investigation as it is realized that stimulation of 
neogenesis in the adult pancreas may lead to pancreatic hyperplasia, β-cell 
maturation/survival and eventual pancreatic dysfunction.  
4.3. Adverse effects of Buchu water 
Buchu is an indigenous plant (herb) species from the Cape regions of South Africa 
which has been used commercially in tea, perfume, herbal tonics and lotions [Moolla et 
al., 2007]. In recent years, the herb’s medicinal uses were explored and research has 
accredited these plants with the possession of diuretic, anti-inflammatory and anti-septic 
properties [Moolla and Viljoen, 2008]. It should be noted that even though Buchu is a 
naturally occurring plant it does not necessarily classify it as safe. However, Buchu is 
approved by the American FDA for human consumption. Many studies have reported 
adverse effects of herbal remedies [Johnson W, 2007; Peters D, 2009].  
 
 








This study, with regard to the type 1 diabetic model, has confirmed the anti-diabetic 
effect of Buchu water by significantly lowering blood glucose levels of fasted and non-
fasted blood and normalizing IPGTT curves.  This was however not so evident in the 
DIO model utilized.  Despite this, animals lost weight which was mainly intra-peritoneal 
fat in these animals.   
 
5.2 Limitations of this study 
The current study was done on male Wister rats only. Effects on female animals may be 
different.  In respect to the DIO model, the effect of Buchu water on insulin resistance 
via adipose tissue secretes (adipokines and cytokines) was not investigated. Such an 
analysis could have shed more light on the metabolic effects observed.   The effects on 
pancreatic tissue of the type 1 diabetic animals were also not studied. In view of the 
results obtained in the DIO animals, this is deemed important. Determination of the 
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5.3 Future perspectives 
 The liver tissue of animals after ingestion of Buchu water should be studied to 
ascertain metabolic changes and possible toxicity. 
 The kidneys should be studied especially with respect to the expression of the 
SGLT-2 glucose transporter. This should be accompanied by a study of the urine 
itself to determine kidney function. 
 The studies on the soleus muscle which is a slow twitch muscle, should be extended 
to e.g. the gastrocnemius muscle. The latter may show more pronounced changes.  
 The effect of Buchu water on weight loss should be studied in more detail.  
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